|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/06/21 Apria, Inc. 10-Q 6/30/21 67:8.7M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.13M
2: EX-10.1 Material Contract HTML 43K
3: EX-10.2 Material Contract HTML 47K
4: EX-10.3 Material Contract HTML 62K
5: EX-31.1 Certification -- §302 - SOA'02 HTML 24K
6: EX-31.2 Certification -- §302 - SOA'02 HTML 24K
7: EX-32.1 Certification -- §906 - SOA'02 HTML 22K
8: EX-32.2 Certification -- §906 - SOA'02 HTML 22K
15: R1 Document and Entity Information HTML 73K
16: R2 Condensed Consolidated Balance Sheets HTML 106K
17: R3 Condensed Consolidated Balance Sheets HTML 37K
(Parenthetical)
18: R4 Condensed Consolidated Statements of Income HTML 92K
19: R5 Condensed Consolidated Statements of Shareholders' HTML 59K
Equity (Deficit)
20: R6 Condensed Consolidated Statements of Cash Flows HTML 110K
21: R7 Summary of Significant Accounting Policies HTML 224K
22: R8 Intangible Assets HTML 92K
23: R9 Debt HTML 72K
24: R10 Stock-Based Compensation HTML 152K
25: R11 Income Taxes HTML 26K
26: R12 Leases HTML 68K
27: R13 Commitments and Contingencies HTML 29K
28: R14 Certain Relationships and Related-Party HTML 27K
Transactions
29: R15 Subsequent Event HTML 22K
30: R16 Summary of Significant Accounting Policies HTML 279K
(Policies)
31: R17 Summary of Significant Accounting Policies HTML 186K
(Tables)
32: R18 Intangible Assets (Tables) HTML 93K
33: R19 Debt (Tables) HTML 72K
34: R20 Stock-Based Compensation (Tables) HTML 148K
35: R21 Leases (Tables) HTML 67K
36: R22 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 57K
Company Background (Details)
37: R23 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 67K
Fee-for-Service Net Revenues and Capitation
Revenues (Details)
38: R24 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 41K
Concentration of Credit Risk and Accounts
Receivable (Details)
39: R25 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 49K
Patient Equipment, Property, Equipment and
Improvements and Capitalized Software (Details)
40: R26 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 25K
Contract Costs, Home Respiratory Therapists Costs
and Distribution Expenses (Details)
41: R27 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 32K
Amounts accrued as Current and Long-term
Liabilities (Details)
42: R28 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 28K
Stock-Based Compensation and Income Taxes
(Details)
43: R29 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 37K
Business Segments - Net Revenues (Details)
44: R30 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 72K
Earnings per share (Details)
45: R31 INTANGIBLE ASSETS - Summary of Intangible assets HTML 47K
(Details)
46: R32 INTANGIBLE ASSETS - Amortization expense (Details) HTML 37K
47: R33 DEBT - Schedule of Long Term Debt (Details) HTML 29K
48: R34 DEBT - Additional Information (Details) HTML 53K
49: R35 DEBT - Schedule of Additional Margin and HTML 42K
Commitment Fees Payable on TLA and Available
Revolver (Details)
50: R36 DEBT - Summary of Expected Principal Repayments HTML 29K
(Details)
51: R37 DEBT - Revolver and Interest Expense (Details) HTML 38K
52: R38 STOCK-BASED COMPENSATION - Profit Interest Units HTML 50K
(Details)
53: R39 STOCK-BASED COMPENSATION - Stock Appreciation HTML 82K
Rights (Details)
54: R40 STOCK-BASED COMPENSATION - Schedule of Activity HTML 46K
for Unvested Shares (Details)
55: R41 STOCK-BASED COMPENSATION - Restricted Stock Awards HTML 73K
(Details)
56: R42 STOCK-BASED COMPENSATION - CFO Restricted Stock HTML 63K
Units (Details)
57: R43 STOCK-BASED COMPENSATION - Long Term Incentive HTML 56K
Plan (Details)
58: R44 Income Taxes (Details) HTML 27K
59: R45 Leases (Details) HTML 26K
60: R46 Leases - Components of lease expense (Details) HTML 29K
61: R47 LEASES - Supplemental information (Details) HTML 30K
62: R48 Commitments and Contingencies (Details) HTML 55K
63: R49 Certain Relationships and Related-Party HTML 51K
Transactions (Details)
65: XML IDEA XML File -- Filing Summary XML 113K
14: XML XBRL Instance -- tmb-20210630x10q_htm XML 2.35M
64: EXCEL IDEA Workbook of Financial Reports XLSX 83K
10: EX-101.CAL XBRL Calculations -- tmb-20210630_cal XML 119K
11: EX-101.DEF XBRL Definitions -- tmb-20210630_def XML 596K
12: EX-101.LAB XBRL Labels -- tmb-20210630_lab XML 1.30M
13: EX-101.PRE XBRL Presentations -- tmb-20210630_pre XML 963K
9: EX-101.SCH XBRL Schema -- tmb-20210630 XSD 178K
66: JSON XBRL Instance as JSON Data -- MetaLinks 324± 487K
67: ZIP XBRL Zipped Folder -- 0001558370-21-010642-xbrl Zip 273K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM i 10-Q
(Mark One)
i ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended i June 30, 2021
or
i ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from to
Commission File Number: i 001-40053
i Apria, Inc.
(Exact name of registrant as specified in its charter)
| |
i Delaware | i 82-4937641 |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification Number) |
i 7353 Company Drive
i Indianapolis, i Indiana i 46237
(Address of Principal Executive Offices)
( i 800) i 990-9799
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| | |
Title of each class | Trading symbol(s) | Name of exchange on which registered |
i Common Stock, $0.01 par value per share | i APR | The i Nasdaq Global Select Market LLC |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. i Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). i Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| | | | | |
Large accelerated filer | ☐ | Accelerated filer | ☐ | | |
| | | | | |
i Non-accelerated filer | ☒ | Smaller reporting company | i ☐ | Emerging growth company | i ☐ |
| | | | | |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes i ☐ No ☒
As of July 28, 2021, there were i 35,256,478 shares of the registrant’s common stock outstanding.
Apria, Inc.
Quarterly Report on Form 10-Q
For the quarterly period ended June 30, 2021
|
| |
| Page | |
|---|---|---|---|---|---|
| | | | | |
| | | | ||
| | | | | |
| | 5 | | ||
| | | | | |
| | Condensed Consolidated Balance Sheets as of June 30, 2021 (Unaudited) and December 31, 2020 | | 5 | |
| | | | | |
| | | 6 | | |
| | | | | |
| | | 7 | | |
| | | | | |
| | | 8 | | |
| | | | | |
| | Notes to Condensed Consolidated Financial Statements (Unaudited) | | 9 | |
| | | | | |
| Management’s Discussion and Analysis of Financial Condition and Results of Operations | | 26 | | |
| | | | | |
| | 40 | | ||
| | | | | |
| | 40 | | ||
| | | | | |
| | | | ||
| | | | | |
| | 40 | | ||
| | | | | |
| | 41 | | ||
| | | | | |
| | 41 | | ||
| | | | | |
| | 41 | | ||
| | | | | |
| | 41 | | ||
| | | | | |
| | 42 | | ||
| | | | | |
| | 42 | | ||
| | | | | |
| | | | | |
| | | | | |
| | | | |
2
Apria, Inc.
Quarterly Report on Form 10-Q
For the quarterly period ended June 30, 2021
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q (this “report”) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which involve certain known and unknown risks and uncertainties. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “could,” “seeks,” “predicts,” “intends,” “trends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words. Such forward-looking statements are subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Our actual results or outcomes may differ materially from those anticipated. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made. We assume no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Our actual results may differ significantly from any results expressed or implied by any forward-looking statements. A summary of the principal risk factors that might cause our actual results to differ from our forward-looking statements is set forth below. The following is only a summary of the principal risks that may materially adversely affect our business, financial condition and results of operations. This summary should be read in conjunction with the more complete discussion of the risk factors we face, which are set forth under Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (the “2020 Form 10-K”) and Part II, Item 1A. “Risk Factors” in this report. Such risks and uncertainties include, but are not limited to, the following:
| ● | the novel coronavirus (“COVID-19”) pandemic, including the emergence of variant strains of the virus, and the global attempt to contain it may harm our business, results of operations and ability to execute on our business plan; |
| ● | our capitation arrangements may prove unprofitable if actual utilization rates exceed our assumptions; |
| ● | our contracts with third-party healthcare payors, including government and commercial payors (“Payors”), including those with organizations that represent a significant portion of our business, are subject to renegotiation or termination which could result in a decrease in our revenue and profits; |
| ● | we depend on reimbursements by Payors, which could lead to delays and uncertainties in the reimbursement process; |
| ● | rising cost of materials, equipment, and labor, as well as shortage of drivers and clinicians could adversely impact our result of operations and cash flow and our ability to timely serve patients; |
| ● | possible changes in the mix of patients and products and services provided, as well as Payor mix and payment methodologies, could have a material adverse effect on our business, financial condition, results of operations, cash flow, capital resources and liquidity; |
| ● | recalls of any of our products, or the discovery of serious safety issues with our products could have a significant adverse impact on our business; |
| ● | if we are unable to provide consistently high quality of care, our business will be adversely impacted; |
3
| ● | our reliance on relatively few vendors for the majority of our patient equipment and supplies and excise taxes which are to be imposed on certain manufacturers of such items could adversely affect our ability to operate; |
| ● | the home healthcare industry is highly competitive and fragmented, with limited barriers to entry which may make it susceptible to vertical integration by manufacturers, Payors, providers (such as hospital systems) or disruptive new entrants; |
| ● | we may be adversely affected by consolidation among health insurers and other industry participants; |
| ● | there is an inherent risk of liability in the provision of healthcare services; damage to our reputation or our failure to adequately insure against losses, including from substantial claims and litigation, could have an adverse impact on our operations, financial condition, or prospects; |
| ● | the current economic uncertainty, deepening of any economic downturn, continued deficit spending by the federal government or state budget pressures may result in a reduction in payments and covered services; |
| ● | changes in home healthcare technology and/or product and therapy innovations may make the services we currently provide obsolete or less competitive; |
| ● | reductions in Medicare, Medicaid and commercial Payor reimbursement rates could have a material adverse effect on our results of operations and financial condition; |
| ● | if we fail to comply with applicable laws and regulations, we could suffer penalties or be required to make significant changes to our operations; |
| ● | we have been, are and could become the subject of federal and state investigations and compliance reviews; |
| ● | if we fail to maintain required licenses, certifications, or accreditation, or if we do not fully comply with requirements to provide notice to or obtain approval from regulatory authorities due to changes in our ownership structure or operation, it could adversely impact our operations; |
| ● | a cyber-attack, a security breach, or the improper disclosure or use of protected health information could cause a loss of confidential data, give rise to remediation and other expenses, expose us to liability under the Health Insurance Portability and Accountability Act of 1996, consumer protection, common law or other legal theories, subject us to litigation and federal and state governmental inquiries, damage our reputation, and otherwise be disruptive to our business; and |
| ● | affiliates of The Blackstone Group Inc. (our “Sponsor”) are our current majority owners and their interests may conflict with ours or yours in the future. |
We urge you to carefully consider the foregoing summary together with the risks discussed in Part I, Item 1A. “Risk Factors” of the 2020 Form 10-K and both Part I, Item 2. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Part II, Item 1A. “Risk Factors” in this report.
WEBSITE AND SOCIAL MEDIA DISCLOSURE
We use our website (www.apria.com) and our corporate Facebook (www.facebook.com/ ApriaHealthcareCareers), LinkedIn (www.linkedin.com/company/Apria-Healthcare), Vimeo (www.vimeo.com/Apria, www.vimeo.com/ApriaCareers, and www.vimeo.com/ApriaMarketing) and YouTube (www.youtube.com/channel/ UCQSJ0Hrf1LJGT3_L6TlDEFQ/featured) accounts as channels of distribution of Company information. The information we post through these channels may be deemed material. Accordingly, investors should monitor these channels, in addition to following our press releases, Securities and Exchange Commission filings and public conference calls and webcasts. The contents of our website and social media channels are not, however, a part of this report.
4
PART I —FINANCIAL INFORMATION
Item 1. Financial Statements
APRIA, INC.
Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)
| | | | | | |
| | | | | | |
| | June 30, | | |||
|
| 2021 |
| 2020 | ||
ASSETS | | | (unaudited) |
| |
|
CURRENT ASSETS | | |
|
| |
|
Cash and cash equivalents | | $ | i 205,944 | | $ | i 195,197 |
Accounts receivable | |
| i 77,640 | |
| i 74,774 |
Inventories | |
| i 6,919 | |
| i 6,680 |
Prepaid expenses and other current assets | |
| i 27,374 | |
| i 24,003 |
TOTAL CURRENT ASSETS | |
| i 317,877 | |
| i 300,654 |
PATIENT EQUIPMENT, less accumulated depreciation of $ i 355,184 and $ i 356,888 as of June 30, 2021 and December 31, 2020, respectively | |
| i 216,869 | |
| i 223,972 |
PROPERTY, EQUIPMENT AND IMPROVEMENTS, NET | |
| i 24,553 | |
| i 25,419 |
INTANGIBLE ASSETS, NET | |
| i 61,209 | |
| i 61,497 |
OPERATING LEASE RIGHT-OF-USE ASSETS | |
| i 58,384 | |
| i 57,869 |
DEFERRED INCOME TAXES, NET | |
| i 6,681 | |
| i 18,258 |
OTHER ASSETS | |
| i 18,482 | |
| i 17,315 |
TOTAL ASSETS | | $ | i 704,055 | | $ | i 704,984 |
| | | | | | |
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | |
|
| |
|
|
CURRENT LIABILITIES | |
|
| |
|
|
Accounts payable | | $ | i 104,174 | | $ | i 116,886 |
Accrued payroll and related taxes and benefits | |
| i 45,251 | |
| i 55,628 |
Other accrued liabilities | |
| i 38,284 | |
| i 33,513 |
Deferred revenue | |
| i 26,820 | |
| i 25,821 |
Current portion of operating lease liabilities | |
| i 23,139 | |
| i 23,977 |
Current portion of long-term debt | |
| i 26,042 | |
| i 20,833 |
TOTAL CURRENT LIABILITIES | |
| i 263,710 | |
| i 276,658 |
LONG-TERM DEBT, less current portion | |
| i 361,277 | |
| i 376,389 |
OPERATING LEASE LIABILITIES, less current portion | |
| i 36,812 | |
| i 35,358 |
OTHER NONCURRENT LIABILITIES | |
| i 40,583 | |
| i 42,924 |
TOTAL LIABILITIES | |
| i 702,382 | |
| i 731,329 |
COMMITMENTS AND CONTINGENCIES (Note 7) | |
|
| |
|
|
STOCKHOLDERS’ EQUITY (DEFICIT) | |
|
| |
|
|
Preferred stock, $ i i 0.01 / par value: i i 100,000,000 / authorized; i i no / shares issued as of June 30, 2021 and February 10, 2021 (Note 1) | | | | | | |
Common stock, $ i i 0.01 / par value: i i 1,000,000,000 / authorized; i 35,256,256 and i 35,210,915 shares issued and outstanding as of June 30, 2021 and February 10, 2021, respectively (Note 1) | | | i 353 | | | — |
Additional paid-in capital | |
| i 956,632 | |
| i 954,087 |
Accumulated deficit | |
| ( i 955,312) | |
| ( i 980,432) |
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT) | |
| i 1,673 | |
| ( i 26,345) |
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | | $ | i 704,055 | | $ | i 704,984 |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
5
APRIA, INC.
Condensed Consolidated Statements of Income
(In thousands, except share and per share data)
(Unaudited)
| | | | | | | | | | | | |
|
| Three Months Ended | | Six Months Ended | ||||||||
|
| June 30, | | |||||||||
| | 2021 |
| 2020 |
| 2021 |
| 2020 | ||||
Net revenues: |
| |
|
| |
| | |
|
| |
|
Fee-for-service arrangements | | $ | i 229,167 | | $ | i 212,822 | | $ | i 447,521 | | $ | i 426,184 |
Capitation | |
| i 57,112 | |
| i 56,120 | |
| i 114,032 | |
| i 111,984 |
TOTAL NET REVENUES | |
| i 286,279 | |
| i 268,942 | |
| i 561,553 | |
| i 538,168 |
Costs and expenses: | |
|
| |
|
| |
|
| |
|
|
Cost of net revenues: | |
|
| |
|
| |
|
| |
|
|
Product and supply costs | |
| i 50,599 | |
| i 47,307 | |
| i 103,914 | |
| i 96,371 |
Patient equipment depreciation | |
| i 25,159 | |
| i 25,655 | |
| i 50,885 | |
| i 50,736 |
Home respiratory therapists costs | |
| i 4,264 | |
| i 3,780 | |
| i 8,322 | |
| i 8,862 |
Other | |
| i 4,726 | |
| i 4,125 | |
| i 8,545 | |
| i 9,252 |
TOTAL COST OF NET REVENUES | |
| i 84,748 | |
| i 80,867 | |
| i 171,666 | |
| i 165,221 |
Selling, distribution and administrative | |
| i 169,275 | |
| i 174,793 | |
| i 346,563 | |
| i 349,436 |
TOTAL COSTS AND EXPENSES | |
| i 254,023 | |
| i 255,660 | |
| i 518,229 | |
| i 514,657 |
OPERATING INCOME | |
| i 32,256 | |
| i 13,282 | |
| i 43,324 | |
| i 23,511 |
Interest expense | |
| i 2,928 | |
| i 1,243 | |
| i 5,944 | |
| i 2,930 |
Interest income | |
| ( i 36) | |
| ( i 87) | |
| ( i 91) | |
| ( i 378) |
INCOME BEFORE INCOME TAXES | |
| i 29,364 | |
| i 12,126 | |
| i 37,471 | |
| i 20,959 |
Income tax expense | |
| i 8,788 | |
| i 3,997 | |
| i 12,351 | |
| i 6,391 |
NET INCOME | | $ | i 20,576 | | $ | i 8,129 | | $ | i 25,120 | | $ | i 14,568 |
| | | | | | | | | | | | |
| | | Three | | | | | | | | ||
| | | Months Ended | | | | | through | | | | |
| | | | | | | | | | |||
Basic and diluted earnings per share: | | | | | | | | | | | | |
Net income attributable to common stockholders | | $ | i 20,576 | | | | | $ | i 23,581 | | | |
Weighted average common shares outstanding: | | | | | | | | | | | | |
Basic | | | i 35,238,773 | | | | | | i 35,228,894 | | | |
Diluted | | | i 38,067,371 | | | | | | i 37,980,369 | | | |
Net income per common share: | |
|
| |
|
| |
|
| |
|
|
Basic | | $ | i 0.58 | | | | | $ | i 0.67 | |
| |
Diluted | | $ | i 0.54 | | | | | $ | i 0.62 | | | |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
6
APRIA, INC.
Condensed Consolidated Statements of Stockholders’ Equity (Deficit)
(In thousands, except share data)
| | | | | | | | | | | | | | | | | | | |
| | Three Months Ended | |||||||||||||||||
| | | | | |
| | | | |
| Additional |
| | |
| Total | ||
| | Preferred Stock | | Common Stock | | Paid-In | | Accumulated | | Stockholders’ | |||||||||
|
| Shares |
| Amount |
| Shares |
| Amount |
| Capital |
| Deficit |
| Equity (Deficit) | |||||
Balance as of March 31, 2021 (unaudited) | | — | | $ | — |
| i 35,210,915 | | $ | i 352 | | $ | i 956,567 | | $ | ( i 975,888) | | $ | ( i 18,969) |
Distributions | | — | | | — | | — | | | — | | | ( i 281) | | | — | | | ( i 281) |
Stock-based compensation | | — | |
| — |
| — | |
| — | |
| i 1,457 | |
| — | |
| i 1,457 |
Common stock issued upon exercise of stock appreciation rights, net of shares withheld for tax | | — | | | — | | i 45,341 | | | i 1 | | | ( i 1,111) | | | — | | | ( i 1,110) |
Net income | | — | |
| — |
| — | |
| — | |
| — | |
| i 20,576 | |
| i 20,576 |
Balance as of June 30, 2021 (unaudited) | | — | | $ | — |
| i 35,256,256 | | $ | i 353 | | $ | i 956,632 | | $ | ( i 955,312) | | $ | i 1,673 |
| | | | | | | | | | | | | | | | | | | |
| | Six Months Ended | |||||||||||||||||
| | | | | |
| | | | |
| Additional |
| | |
| Total | ||
| | Preferred Stock | | Common Stock | | Paid-In | | Accumulated | | Stockholders’ | |||||||||
| | Shares | | Amount | | Shares | | Amount | | Capital | | Deficit | | Equity (Deficit) | |||||
Balance as of December 31, 2020 | | — | | $ | — |
| — | | $ | — | | $ | i 954,087 | | $ | ( i 980,432) | | $ | ( i 26,345) |
IPO Transactions (Note 1) | | — | | | — | | i 35,210,915 | | | i 352 | | | ( i 352) | | | — | | | — |
Distributions | | — | | | — | | — | | | — | | | ( i 493) | | | — | | | ( i 493) |
Stock-based compensation | | — | |
| — |
| — | |
| — | |
| i 4,501 | |
| — | |
| i 4,501 |
Common stock issued upon exercise of stock appreciation rights, net of shares withheld for tax | | — | | | — | | i 45,341 | | | i 1 | | | ( i 1,111) | | | — | | | ( i 1,110) |
Net income | | — | |
| — |
| — | |
| — | |
| — | |
| i 25,120 | |
| i 25,120 |
Balance as of June 30, 2021 (unaudited) | | — | | $ | — |
| i 35,256,256 | | $ | i 353 | | $ | i 956,632 | | $ | ( i 955,312) | | $ | i 1,673 |
| | | | | | | | | | | | | | | | | | | |
| | Three Months Ended | |||||||||||||||||
| | | | | |
| | | | |
| Additional |
| | |
| Total | ||
| | Preferred Stock | | Common Stock | | Paid-In | | Accumulated | | Stockholders’ | |||||||||
| | Shares | | Amount | | Shares | | Amount | | Capital | | Deficit | | Equity | |||||
Balance as of March 31, 2020 (unaudited) | | — | | $ | — |
| — | | $ | — | | $ | i 1,161,566 | | $ | ( i 1,020,132) | | $ | i 141,434 |
Stock-based compensation | | — | | | — |
| — | | | — | |
| i 465 | |
| — | |
| i 465 |
Net income | | — | | | — |
| — | | | — | |
| — | |
| i 8,129 | |
| i 8,129 |
Balance as of June 30, 2020 (unaudited) | | — | | $ | — |
| — | | $ | — | | $ | i 1,162,031 | | $ | ( i 1,012,003) | | $ | i 150,028 |
| | | | | | | | | | | | | | | | | | | |
| | Six Months Ended | |||||||||||||||||
| | | | | |
| | | | |
| Additional |
| | |
| Total | ||
| | Preferred Stock | | Common Stock | | Paid-In | | Accumulated | | Stockholders’ | |||||||||
| | Shares | | Amount | | Shares | | Amount | | Capital | | Deficit | | Equity | |||||
Balance as of December 31, 2019 | | — | | $ | — |
| — | | $ | — | | $ | i 1,161,087 | | $ | ( i 1,026,571) | | $ | i 134,516 |
Stock-based compensation | | — | | | — |
| — | | | — | |
| i 944 | |
| — | |
| i 944 |
Net income | | — | | | — |
| — | | | — | |
| — | |
| i 14,568 | |
| i 14,568 |
Balance as of June 30, 2020 (unaudited) | | — | | $ | — |
| — | | $ | — | | $ | i 1,162,031 | | $ | ( i 1,012,003) | | $ | i 150,028 |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
7
APRIA, INC.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
| | | | | | |
|
| Six Months Ended | ||||
|
| |||||
|
| 2021 |
| 2020 | ||
OPERATING ACTIVITIES |
| |
|
| |
|
Net income | | $ | i 25,120 | | $ | i 14,568 |
Items included in net income not requiring cash: | |
|
| |
|
|
Depreciation | |
| i 57,648 | | | i 57,904 |
Amortization of intangible assets | |
| i 937 | | | i 287 |
Non-cash lease expense | |
| i 13,495 | | | i 13,769 |
Deferred income taxes | |
| i 11,577 | | | i 6,197 |
Stock-based compensation | |
| i 4,501 | | | i 944 |
Amortization of deferred debt issuance costs | |
| i 543 | | | i 247 |
Loss on sale of patient equipment and other | |
| i 3,125 | | | i 2,665 |
Changes in operating assets and liabilities: | |
| | | | |
Accounts receivable | |
| ( i 2,866) | | | i 7,563 |
Inventories | |
| ( i 239) | | | i 93 |
Prepaid expenses and other assets | |
| ( i 4,538) | | | ( i 5,252) |
Accounts payable | |
| ( i 5,649) | | | ( i 21,236) |
Accrued payroll and related taxes and benefits | |
| ( i 10,377) | | | ( i 1,726) |
Operating lease liabilities | | | ( i 13,393) | | | ( i 12,317) |
Deferred revenue | |
| i 999 | | | i 1,447 |
Legal reserve | | | i 1,250 | | | i 12,800 |
Accrued expenses | |
| i 502 | | | i 6,645 |
NET CASH PROVIDED BY OPERATING ACTIVITIES | |
| i 82,635 | |
| i 84,598 |
INVESTING ACTIVITIES | |
|
| |
|
|
Purchases of patient equipment and property, equipment and improvements | |
| ( i 61,211) | | | ( i 55,920) |
Proceeds from sale of patient equipment and other | |
| i 7,996 | | | i 9,566 |
Cash paid for acquisition | |
| ( i 650) | |
| — |
NET CASH USED IN INVESTING ACTIVITIES | |
| ( i 53,865) | |
| ( i 46,354) |
FINANCING ACTIVITIES | | | | | | |
Payments on asset financing | | | ( i 6,003) | | | ( i 13,189) |
Payments on debt | | | ( i 10,417) | | | — |
Distribution payments | | | ( i 493) | | | — |
Payments for tax withholdings from equity-based compensation activity | | | ( i 1,110) | | | — |
NET CASH USED IN FINANCING ACTIVITIES | |
| ( i 18,023) | |
| ( i 13,189) |
NET DECREASE IN CASH AND CASH EQUIVALENTS | | | i 10,747 | | | i 25,055 |
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD | | | i 195,197 | | | i 74,691 |
CASH AND CASH EQUIVALENTS AT END OF PERIOD | | $ | i 205,944 | | $ | i 99,746 |
SUPPLEMENTAL DISCLOSURES—See Note 3 – Debt and Note 5 – Income Taxes for a discussion of cash paid for interest and income taxes, respectively.
NON-CASH INVESTING AND FINANCING TRANSACTIONS—Purchases of patient equipment and property, equipment and improvements exclude purchases that remain unpaid at the end of the respective period. Such amounts are included in the following period’s purchases. Unpaid purchases were $ i 48.7 million and $ i 55.1 million as of June 30, 2021 and December 31, 2020, respectively. Unpaid purchases include $ i 14.8 million and $ i 15.7 million of patient equipment and property, equipment and improvements acquired under extended payment terms as of June 30, 2021 and December 31, 2020, respectively. See Note 6 - Leases for a discussion of right-of-use assets obtained in exchange for new operating lease liabilities.
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
8
APRIA, INC.
Notes to Condensed Consolidated Financial Statements
(Dollars in thousands, unless otherwise stated)
(Unaudited)
i1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
iBasis of Presentation—The accompanying unaudited condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and are presented in U.S. dollars. These unaudited condensed consolidated financial statements include the accounts of Apria, Inc. (the “Company” or “Apria”) and its subsidiaries. The Company had no items of other comprehensive income; as such, its comprehensive income is the same as the net income for all periods presented. Intercompany transactions and accounts have been eliminated in consolidation. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and, in the opinion of management, reflect all normal recurring adjustments necessary for the fair statement of the consolidated results for these periods. Interim period results are not necessarily indicative of the results that may be expected for the full fiscal year.
In connection with the completion of the Company’s initial public offering (the “IPO” or “offering”), the Company underwent a reorganization transaction (see Initial Public Offering) and Apria Healthcare Group Inc. (“Apria Healthcare Group”) became an indirect wholly-owned subsidiary of the Company on February 10, 2021. As a result of the reorganization transaction, the Company directly or indirectly owns all of the equity interests in Apria Healthcare Group and is the holding company of the Company’s business. The merger was accounted for as a reorganization of entities under common control. As a result, the consolidated financial statements of the Company recognize the assets and liabilities received in the merger at their historical carrying amounts as reflected in the historical consolidated financial statements of Apria Healthcare Group, the accounting predecessor. Furthermore, prior to the offering, the Company’s business was conducted through Apria Healthcare Group, which did not have a common capital structure with Apria, Inc. and therefore, the Company has not presented the historical capital structure of Apria Healthcare Group within the financial statements. As such, the Company computed earnings per share (“EPS”) for the period the Company’s common stock was outstanding during 2021, referred to as the Post-IPO period. The Company has defined the Post-IPO period as February 10, 2021, the effective date of the pre-IPO reorganization and the completion of the offering, through June 30, 2021. See below for a discussion of the reorganization transaction and EPS calculations.
iCompany Background—Apria, Inc., a Delaware corporation formed on March 22, 2018, is the financial reporting entity following the Company’s IPO in February 2021.
The Company operates in the home healthcare segment of the healthcare industry, providing a variety of clinical and administrative support services and related products and supplies, most of which are prescribed by a physician as part of a care plan. Essentially all products and services offered by the Company are provided through the Company’s network of approximately i 300 branch, distribution and other locations, which are located throughout the United States. The Company provides services and products in i one operating segment: home respiratory therapy/home medical equipment. The Company provides patients in their homes with products and services which are primarily paid for by a third-party payor, such as Medicare, Medicaid, a managed care plan or another third-party insurer. Sales are primarily derived from referral sources such as hospital discharge planners, medical groups or independent physicians.
Initial public offering— In February 2021, the Company completed an underwritten offering (in which entities associated with The Blackstone Group Inc. (the “selling stockholders”) sold an aggregate of i 8,625,000 shares of common stock, including i 1,125,000 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares. The Company did not receive any proceeds from the shares sold by the selling stockholders and the Company incurred offering related expenses of approximately $ i 6.0 million, which were incurred and paid on the Company’s behalf prior to the offering by Apria Healthcare Group.
In connection with the completion of the offering, the Company underwent a reorganization transaction. On February 10, 2021, a newly formed indirect subsidiary of the Company merged with and into Apria Healthcare Group,
/ /9
with Apria Healthcare Group surviving. As a result, Apria Healthcare Group became an indirect wholly-owned subsidiary of the Company. The Company’s stockholders who previously held their ownership interest prior to the IPO through Apria Holdings LLC (“Holdings”) (as the i 100% direct owner of Apria Healthcare Group) received an aggregate of i 35,210,915 shares of newly issued common stock of the Company with a par value of $ i 0.01 per share.
In connection with the IPO, the Company’s certificate of incorporation (the “Charter”) and bylaws were each amended and restated, effective on February 10, 2021. The Charter authorizes i 1,000,000,000 shares of common stock with a par value of $ i 0.01 per share. Each share of common stock is entitled to i one vote per share on all matters on which stockholders are entitled to vote generally, including the election or removal of directors. The Charter also authorizes i 100,000,000 shares of preferred stock, par value $ i 0.01 per share, of which there were i i no / shares of preferred stock issued or outstanding immediately after the IPO or as of June 30, 2021.
iUse of Accounting Estimates—The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Among the significant estimates affecting the unaudited condensed consolidated financial statements are those related to revenue recognition and the resulting accounts receivable, self-insurance reserves, long-lived assets, stock-based compensation, legal reserves and income taxes.
iFee-for-Service Net Revenues—Revenues are recognized under fee-for-service arrangements for equipment the Company rents to patients and sales of equipment, supplies and other items the Company sells to patients.
Rental and sale net revenues under fee-for-service arrangements disaggregated by each core service line item were:
i
| | | | | | | | | | | | | | | | | | | |
| | Three Months Ended June 30, | | ||||||||||||||||
| | 2021 | | 2020 | | ||||||||||||||
| | | | | | | | Total Fee- | | | | | | | | Total Fee- | | ||
| | | | | | | | For- | | | | | | | | For- | | ||
(dollars in thousands) |
| Rental |
| Sale |
| Service |
| Rental |
| Sale |
| Service | | ||||||
Home respiratory therapy | | $ | i 102,247 | | $ | i 794 | | $ | i 103,041 | | $ | i 97,536 | | $ | i 1,341 | | $ | i 98,877 | |
Obstructive sleep apnea treatment | |
| i 23,319 | |
| i 73,484 | |
| i 96,803 | |
| i 21,124 | |
| i 65,639 | |
| i 86,763 | |
Negative pressure wound therapy | |
| i 6,511 | |
| i 1,670 | |
| i 8,181 | |
| i 6,360 | |
| i 517 | |
| i 6,877 | |
Other equipment and services | |
| i 9,895 | |
| i 11,247 | |
| i 21,142 | |
| i 9,916 | |
| i 10,389 | |
| i 20,305 | |
Total | | $ | i 141,972 | | $ | i 87,195 | | $ | i 229,167 | | $ | i 134,936 | | $ | i 77,886 | | $ | i 212,822 | |
| |
| i 62.0 | % |
| i 38.0 | % |
| i 100.0 | % |
| i 63.4 | % |
| i 36.6 | % |
| i 100.0 | % |
| | | | | | | | | | | | | | | | | | | |
| | Six Months Ended June 30, | | ||||||||||||||||
| | 2021 | | 2020 | | ||||||||||||||
| | | | | | | | Total Fee- | | | | | | | | Total Fee- | | ||
| | | | | | | | For- | | | | | | | | For- | | ||
(dollars in thousands) |
| Rental |
| Sale |
| Service |
| Rental |
| Sale |
| Service | | ||||||
Home respiratory therapy | | $ | i 202,059 | | $ | i 1,334 | | $ | i 203,393 | | $ | i 194,643 | | $ | i 2,081 | | $ | i 196,724 | |
Obstructive sleep apnea treatment | |
| i 43,785 | |
| i 143,955 | |
| i 187,740 | |
| i 41,727 | |
| i 130,733 | |
| i 172,460 | |
Negative pressure wound therapy | |
| i 13,817 | |
| i 2,155 | |
| i 15,972 | |
| i 13,622 | |
| i 1,189 | |
| i 14,811 | |
Other equipment and services | |
| i 19,314 | |
| i 21,102 | |
| i 40,416 | |
| i 20,164 | |
| i 22,025 | |
| i 42,189 | |
Total | | $ | i 278,975 | | $ | i 168,546 | | $ | i 447,521 | | $ | i 270,156 | | $ | i 156,028 | | $ | i 426,184 | |
| |
| i 62.3 | % |
| i 37.7 | % |
| i 100.0 | % |
| i 63.4 | % |
| i 36.6 | % |
| i 100.0 | % |
Rental revenues—Revenue generated from equipment that the Company rents to patients is recognized over the noncancelable rental period, typically i one month, and commences on delivery of the equipment to the patients. The Company evaluates the portfolio of lease contracts at lease commencement and the start of each monthly renewal period to determine if it is reasonably certain that the monthly renewal or purchase options would be exercised. The exercise of monthly renewal or purchase options by a patient has historically not been reasonably certain to occur at lease commencement or subsequent monthly renewal.
Revenues are recorded at amounts estimated to be received under reimbursement arrangements with third-party payors, including private insurers, prepaid health plans, Medicare, Medicaid and patients. Rental revenue, less estimated
/10
adjustments, is recognized as earned on a straight-line basis over the noncancellable lease term. Rental of patient equipment is billed on a monthly basis beginning on the date the equipment is delivered. Since deliveries can occur on any day during a month, the amount of billings that apply to the next month are deferred.
The Company’s lease agreements generally contain lease and non-lease components. Non-lease components primarily relate to supplies. The Company allocates the transaction price to the separate lease and non-lease components that qualify as performance obligations using the stand-alone selling price.
Sale revenues—Revenue related to sales of equipment and supplies is recognized on the date of delivery as this is when control of the promised goods is transferred to patients and is presented net of applicable sales taxes. Revenues are recorded only to the extent it is probable that a significant reversal will not occur in the future as amounts may include implicit price concessions under reimbursement arrangements with third-party payors, including private insurers, prepaid health plans, Medicare, Medicaid and patients. The Company determines the sales transaction price based on contractually agreed-upon rates, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable consideration as part of determining the sales transaction price using historical reimbursement experience, historical sales returns, and other operating trends. Payment terms and conditions vary by contract. The timing of revenue recognition, billing, and cash collection generally results in billed and unbilled accounts receivable.
Capitation Revenues—Revenues are recognized under capitation arrangements with third-party payors for services and equipment for which the Company stands ready to provide to the members of these payors without regard to the actual services provided. The stand-ready obligation generally extends beyond i one year. Revenue is recognized over the month that the members are entitled to healthcare services using the contractual rate for each covered member. The actual number of covered members may vary each month. As a practical expedient, no disclosures have been made related to the amount of variable consideration expected to be recognized in future periods under these capitation arrangements. Capitation payments are typically received in the month members are entitled to healthcare services. Contracts with a single national payor constituted i i 86 / % of total capitation revenues in the three months ended June 30, 2021 and 2020, and i i 86 / % of the total capitation revenues for the six months ended June 30, 2021 and 2020.
iConcentration of Credit Risk—Revenues reimbursed under arrangements with Medicare and Medicaid were approximately i i 21 / % and i i 1 / %, respectively, of total net revenues for the three and six months ended June 30, 2021. Revenues reimbursed under arrangements with Medicare and Medicaid were approximately i 21% and i 1%, respectively, of total net revenues for the three months ended June 30, 2020 and i 19% and i 1%, respectively, of total net revenues for the six months ended June 30, 2020. Contracts with i i two / national payors each constituted i i 23 / % and i i 11 / %, of total net revenues for the three and six months ended June 30, 2021. Contracts with i i two / national payors each constituted i 23% and i 11% of total net revenues for the three months ended June 30, 2020 and i 24% and i 11% of total net revenues for the six months ended June 30, 2020. No other payors represented more than 10% of the Company’s total net revenues in each of the three and six months ended June 30, 2021 and June 30, 2020. As of June 30, 2021 and December 31, 2020, Medicare represented greater than 10% of net accounts receivable.
/ iCash and Cash Equivalents—Cash is maintained with various financial institutions located throughout the United States. Cash account balances may be more than the amounts insured by the Federal Deposit Insurance Corporation; however, management believes the risk of loss to be minimal based on the credit standing of these institutions and has not experienced any losses on its cash and cash equivalents to date. Management considers all highly liquid instruments purchased with an original maturity of less than three months to be cash equivalents.
iAccounts Receivable—Included in accounts receivable are earned but unbilled receivables of $ i 14.2 million and $ i 13.1 million as of June 30, 2021 and December 31, 2020, respectively. Delays ranging from a day up to several weeks between the date of service and billing can occur due to delays in obtaining certain required payor-specific documentation from internal and external sources. Earned but unbilled receivables are aged from date of service and are considered in the analysis of historical performance and collectability.
Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record total net revenues and accounts receivable at their net realizable values. Inherent in these
/11
estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application, claim denial or account review.
Management performs periodic analyses to evaluate accounts receivable balances to ensure that recorded amounts reflect estimated net realizable value. Specifically, management considers historical realization data, accounts receivable aging trends, other operating trends, and the extent of contracted business and business combinations. Also considered are relevant business conditions such as governmental and managed care payor claims processing procedures and system changes.
Additionally, focused reviews of certain large and/or problematic payors are performed. Due to continuing changes in the healthcare industry and third-party reimbursement, it is possible that management’s estimates could change in the near term, which could have an impact on operations and cash flows.
The Company records a reserve for expected credit losses as part of net rental revenue adjustments in order to report rental revenue at an expected collectable amount based on the total portfolio of operating lease receivables for which collectability has been deemed probable.
iInventories—Inventories are stated at the lower of cost (approximate costs determined on the first-in, first-out basis) or net realizable value and consist primarily of respiratory supplies and items used in conjunction with patient equipment.
iPatient Equipment—Patient equipment is stated at cost less depreciation and reserves for non-recoverable and obsolete patient equipment. Patient equipment consists of medical equipment rented to patients on a month-to-month basis. Depreciation is provided using the straight-line method over the estimated useful lives of the equipment, which range from 1 to i 10 years. Patient equipment depreciation is classified in the Company’s unaudited condensed consolidated statements of income within cost of net revenues as the equipment is rented to patients as part of the Company’s primary operations. Depreciation expense for patient equipment was $ i 25.2 million and $ i 25.6 million for the three months ended June 30, 2021 and 2020, respectively, and $ i 50.9 million and $ i 50.7 million for the six months ended June 30, 2021 and 2020, respectively. The reserves for non-recoverable and obsolete patient equipment were $ i 3.6 million and $ i 3.1 million as of June 30, 2021 and December 31, 2020, respectively.
Patient equipment is generally placed for rent; however, it could also be sold to customers. Once the rented equipment is returned to the Company, patient equipment is assessed and repaired as necessary. Patient equipment is typically leased to subsequent patients if its condition is suitable. Upon a sale, the Company records the proceeds of the sale within net revenues and the costs related to the carrying net book value as other costs within cost of net revenues in the Company’s unaudited condensed consolidated statements of income.
Given rental income is generated from such products, purchases of patient equipment are considered an investing activity when paid soon before or after purchase, while other payments made are considered a financing activity within the unaudited condensed consolidated statements of cash flows. Certain unpaid purchases are secured by a security interest in $ i 3.2 million and $ i 5.1 million of patient equipment as of June 30, 2021 and December 31, 2020, respectively. The net loss from the sale of patient equipment is reported as an adjustment to net income within cash provided by operating activities in the unaudited condensed consolidated statements of cash flows.
Property, Equipment and Improvements—Property, equipment and improvements are stated at cost less depreciation. Depreciation is provided using the straight-line method over the estimated useful lives of the assets, which range from 1 to i 15 years or, for leasehold improvements, the shorter of the useful life of the asset or the remaining life of the related lease.
Capitalized Software—Capitalized software costs related to internally developed and purchased software are included in property, equipment and improvements in the unaudited condensed consolidated balance sheets and are amortized using the straight-line method over the estimated useful lives of the assets, which range from three to i five
/12
years. Capitalized costs include direct costs of materials and services incurred in developing or obtaining internal-use software and payroll and benefit costs for employees directly involved in the development of internal-use software. Capitalization of such costs ceases when the project is substantially complete and ready for its intended purpose. Costs incurred during the preliminary and post-implementation stages, as well as software maintenance and training costs, are expensed in the period in which they are incurred. Additions to capitalized internally developed software totaled $ i 1.6 million and $ i 1.1 million for the three months ended June 30, 2021 and 2020, respectively, and $ i 3.0 million and $ i 1.8 million for the six months ended June 30, 2021 and 2020, respectively. Amortization expense for internally developed software was $ i 1.3 million and $ i 1.5 million for the three months ended June 30, 2021 and 2020, respectively, and $ i 2.5 million and $ i 3.0 million for the six months ended June 30, 2021 and 2020, respectively.
iIndefinite-Lived Intangible Assets and Long-Lived Assets—Indefinite-lived intangible assets are not amortized but instead tested at least annually for impairment or more frequently when events or changes in circumstances indicate that the assets might be impaired. The Company performs the annual test for impairment for indefinite-lived intangible assets as of the first day of the fourth quarter.
The Company will first assess qualitative factors to determine whether it is more likely than not that the fair value is less than its carrying amount. If, based on a review of qualitative factors, it is more likely than not that the fair value is less than its carrying amount, the Company will use a quantitative approach, and calculate the fair value and compare it to its carrying amount. If the fair value exceeds the carrying amount, there is no indication of impairment. If the carrying amount exceeds the fair value, an impairment loss is recorded equal to the difference.
Long-lived assets, including property and equipment and purchased definite-lived intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Significant judgment is required in determining whether a potential indicator of impairment of long-lived assets exists and in estimating future cash flows for any necessary impairment tests. Recoverability of assets to be held and used is measured by the comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such an asset is considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell.
The Company did not record any impairment charges related to indefinite-lived intangible assets or long-lived assets for the six months ended June 30, 2021 and 2020.
iFair Value of Financial Instruments—Management is required to disclose the estimated fair value of certain assets and liabilities of financial instruments. Financial instruments are generally defined as cash, evidence of ownership interest in an entity or a contractual obligation that both conveys to one entity a right to receive cash or other financial instruments from another entity and imposes on the other entity the obligation to deliver cash or other financial instruments to the first entity. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate fair value due to their short maturity. The carrying amounts of the Company’s long-term debt, including the Term Loan A Facility (the “TLA”) and Revolving Credit Facility (the “Revolver”), as of June 30, 2021, approximate fair value due to the variable rate nature of the agreements. All debt classifications represent Level 2 fair value measurements.
iLeases—The Company determines if an arrangement is a lease at commencement and performs an evaluation to determine whether the lease should be classified as an operating or finance lease. Operating leases are included in operating lease right-of-use (“ROU”) assets, current portion of operating lease liabilities and operating lease liabilities, less current portion, on the unaudited condensed consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and the related liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate (“IBR”) based on the information available at the lease commencement date in determining the present value of future lease payments. The Company uses market rates from recent secured financing in its determination of the IBR.
13
The operating lease ROU asset also includes any lease payments made to the lessor at or before the commencement date and is adjusted by any lease incentives received. Variable lease payments are not included in the operating lease liability as they cannot be reasonably estimated and are recognized in the period in which the obligation for those payments is incurred. Lease terms may include options to extend or terminate the lease and are included only when it is reasonably certain that the Company will exercise that option. For all asset classes, leases with a lease term of twelve months or less at the lease commencement date are not recorded on the unaudited condensed consolidated balance sheets, as permitted by the short-term lease exception. Lease expense for lease payments is recognized on a straight-line basis over the lease term.
The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company does not have any material subleases. The Company does not have any leases classified as a finance leasing arrangement. As such, all leases are classified as operating leases. See further discussion at Note 6 – Leases.
iProduct and Supply Costs—Product and supply costs presented within total cost of net revenues are comprised primarily of the cost of supplies, equipment and accessories provided to patients.
iContract Costs—The Company pays sales commissions on fee-for-service arrangements in an effort to increase the volume of serviced patients. The Company elected to use the practical expedient to expense sales commissions as incurred since the amortization period would otherwise be less than one year. These costs are included in selling, distribution and administrative (“SD&A”) expenses in the unaudited condensed consolidated statements of income.
iHome Respiratory Therapists Costs—Home respiratory therapists costs presented within total cost of net revenues are comprised primarily of employee salary and benefit costs or contract fees paid to respiratory therapists and other related professionals who are deployed to service a patient. Home respiratory therapy personnel are also engaged in a number of administrative and marketing tasks and, accordingly, these costs are classified within SD&A expenses and were $ i 3.2 million and $ i 3.8 million for the three months ended June 30, 2021 and 2020, respectively, and $ i 6.7 million and $ i 7.9 million for the six months ended June 30, 2021 and 2020, respectively.
/ iDistribution Expenses—Distribution expenses totaled $ i 31.1 million and $ i 28.3 million for the three months ended June 30, 2021 and 2020, respectively, and $ i 62.5 million and $ i 59.4 million for the six months ended June 30, 2021 and 2020, respectively. Such expense represents the cost incurred to coordinate and deliver products and services to the patients. Included in distribution expenses are leasing, maintenance, licensing and fuel costs for the vehicle fleet; salaries and other costs related to drivers and dispatch personnel; and amounts paid to courier and other outside shipping vendors. Such expenses fall within the definition of “shipping and handling” costs and are classified within SD&A expenses and may not be comparable to other companies.
/ iSelf-Insurance—Coverage for certain employee medical claims and benefits, as well as workers’ compensation, professional and general liability, and vehicle liability are self-insured. Amounts accrued for costs of workers’ compensation, medical, professional and general liability, and vehicle liability are classified as current or long-term liabilities based upon an estimate of when the liability will ultimately be paid. Amounts are recorded gross of any estimated recoverable amounts from insurance providers. The estimated recoverable amounts from insurance providers are recorded within prepaid expense and other current assets and other assets on the unaudited condensed consolidated balance sheets based upon an estimate of when they will be received.
Amounts accrued as current liabilities within other accrued liabilities are as follows:
i
| | | | | | |
| | June 30, | | December 31, | ||
(in thousands) |
| 2021 |
| 2020 | ||
Workers’ compensation |
| $ | i 4,984 |
| $ | i 4,780 |
Professional and general liability/vehicle | |
| i 3,712 | |
| i 3,929 |
Medical insurance | |
| i 2,424 | |
| i 2,169 |
/14
Amounts accrued as long-term liabilities within other noncurrent liabilities are as follows:
i
| | | | | | |
| | June 30, | | December 31, | ||
(in thousands) | | 2021 | | 2020 | ||
Workers’ compensation |
| $ | i 17,146 |
| $ | i 17,691 |
Professional and general liability/vehicle | |
| i 5,611 | |
| i 6,554 |
iStock-Based Compensation—The Company accounts for its stock-based awards in accordance with provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) No. 718, Compensation—Stock Compensation. Subsequent to the IPO, the Company has the following types of equity-based compensation awards outstanding: stock appreciation rights (“SARs”), restricted stock units (“RSUs”), performance-based restricted stock units (“PSUs”), Chief Financial Officer (“CFO”) RSUs, and stock-settled long-term incentive plan (“LTIP”) awards.
The Company recognizes compensation expense with respect to SARs based on the fair value of the awards as measured on the grant date. Fair value is not subsequently remeasured unless the conditions on which the award was granted are modified. The determination of fair value at grant date requires the use of estimates, which are based on management’s judgment. Generally, compensation expense for each separately vesting portion of the awards is recognized on a straight-line basis over the vesting period for that portion of the award subject to continued service.
As the CFO RSUs can be settled in either cash or shares of common stock at the election of the holder they are recorded as liability awards. The fair value is measured at the grant date and remeasured each reporting period until settlement. Compensation expense is recognized over the requisite service period subject to continued employment and adjusted each reporting period for changes in the fair value pro-rated for the portion of the requisite service period rendered.
The Company recognizes compensation expense with respect to RSUs and PSUs, or collectively referred to as omnibus plan awards (“Omnibus Plan Awards”), based on the fair value of the awards as measured on the grant date. Fair value is not subsequently remeasured unless the conditions on which the award was granted are modified. For time based only Omnibus Plan Awards, compensation expense for each separately vesting portion of the award is recognized on a straight-line basis over the vesting period for that portion of the award subject to continued service. For Omnibus Plan Awards with performance conditions, compensation expense is recognized over the requisite service period subject to management’s estimation of the probability of vesting of such awards.
The IPO triggered a pre-existing provision under the Company’s 2019 LTIP pursuant to which the incentive awards will be settled in shares of the Company’s common stock. The modification of the award did not result in incremental compensation expense as the fair value of the award was the same immediately prior to and immediately after the modification. Compensation expense is recognized on a straight-line basis over the requisite service period subject to management’s estimation of the probability of vesting of such awards.
iLegal Reserves—The Company is involved in various legal proceedings, claims, and litigation that arise in the ordinary course of business. The Company investigates these matters as they arise and reserves for potential loss in accordance with ASC No. 450, Contingencies. Significant judgment is required in the determination of both the probability of loss and whether the amount of the loss can be reasonably estimated. Estimates are subjective and are made in consultation with internal and external legal counsel. See further discussion at Note 7 – Commitments and Contingencies.
iIncome Taxes—The Company’s provision for income taxes is based on expected income, permanent book/tax differences and statutory tax rates in the various jurisdictions in which the Company operates. Significant management estimates and judgments are required in determining the provision for income taxes.
Deferred income tax assets and liabilities are computed for differences between the carrying amounts of assets and liabilities for financial statement and tax purposes. Deferred income tax assets are required to be reduced by a valuation
15
allowance when it is determined that it is more likely than not that all or a portion of a deferred tax asset will not be realized.
On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (“CARES”) Act was enacted and signed into U.S. law to provide economic relief to individuals and businesses facing economic hardship as a result of the novel coronavirus (“COVID-19”) public health emergency. The CARES Act includes, among other things, provisions relating to payroll tax credits and deferrals, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, and technical corrections to tax depreciation methods for qualified improvement property. As permitted under the CARES Act, the Company has elected to defer certain portions of employer-paid FICA taxes otherwise payable from March 27, 2020 to January 1, 2021, to be paid in i two equal installments on December 31, 2021 and December 31, 2022. As of June 30, 2021 and December 31, 2020, $ i i 14.8 / million of FICA tax payments were deferred, of which $ i i 7.4 / million is included in accrued payroll and related taxes and benefits and $ i i 7.4 / million is included in other noncurrent liabilities on the unaudited condensed consolidated balance sheets.
iBusiness Segments—The Company has evaluated segment reporting in accordance with FASB ASC No. 280, Segment Reporting. The Company’s chief executive officer is its chief operating decision maker. The chief operating decision maker reviews financial information about the business at the enterprise-wide consolidated level when allocating the resources of the Company and assessing business performance. Accordingly, the Company has determined that its business activities comprise a single operating and reporting segment, the home respiratory therapy/home medical equipment segment. Through its single segment, the Company focuses on i three core service lines: home respiratory therapy (including home oxygen and non-invasive ventilation services), obstructive sleep apnea treatment (including continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services) and negative pressure wound therapy. Additionally, the Company supplies a wide range of home medical equipment and other products and services to help improve the quality of life for patients with home care needs.
Net revenues for each core service line were:
i
| | | | | | | | | | | | |
| | Three Months Ended | | Six Months Ended | ||||||||
| | June 30, | | |||||||||
| | 2021 | | 2020 |
| 2021 |
| 2020 | ||||
(in thousands) | | | | | | | | | | | | |
Home respiratory therapy |
| $ | i 116,005 |
| $ | i 111,531 | | $ | i 230,328 |
| $ | i 221,282 |
Obstructive sleep apnea treatment | |
| i 121,479 | |
| i 109,649 | |
| i 235,664 | |
| i 218,984 |
Negative pressure wound therapy | |
| i 10,273 | |
| i 9,631 | |
| i 20,384 | |
| i 19,790 |
Other equipment and services | |
| i 38,522 | |
| i 38,131 | |
| i 75,177 | |
| i 78,112 |
Net revenues | | $ | i 286,279 | | $ | i 268,942 | | $ | i 561,553 | | $ | i 538,168 |
iEarnings per share—Prior to the IPO, the Company’s business was conducted through Apria Healthcare Group, which did not have a common capital structure with Apria, Inc. In connection with the completion of the offering, the Company underwent a reorganization transaction in which Apria Healthcare Group Inc. became an LLC and a newly formed indirect subsidiary of the Company merged with and into Apria Healthcare Group, with Apria Healthcare Group surviving. As a result, Apria Healthcare Group became an indirect wholly-owned subsidiary of the Company. As part of the merger Apria Healthcare Group SAR units were converted to Apria, Inc. SARs and the Company’s stockholders who previously held their ownership interest prior to the IPO through Holdings (as the i 100% direct owner of Apria Healthcare Group) received newly issued common shares. The conversion ratios for SARs and the i three different classes of profit interest units (“PIUs”), which each had different preference rights as detailed in Note 4—Stock-Based Compensation, were determined based on the unit value implied by the per share price of common stock sold in the IPO. See further discussion at Note 1—Summary of Significant Accounting Policies – Initial Public Offering. Based on the complex nature of the reorganization transaction and based on consideration of the equity structure prior to IPO, the Company computed EPS only on a prospective basis for the period the Company’s common stock was outstanding during 2021, referred to as the Post-IPO period. The Company has defined the Post-IPO period as February 10, 2021, the effective date of the pre-IPO reorganization and the completion of the offering, through June 30, 2021. Basic net income per common share represents net income attributable to common stockholders for the Post-IPO period divided by the weighted-average number of common shares outstanding during the Post-IPO period. Diluted net income per common
/16
share is similar to calculating basic net income per common share, except the denominator is increased to include the dilutive effects of stock-based awards except when doing so would be antidilutive.
The computation of net income per common share is presented below:
i
| | | | | | |
| | Three | | |||
| | Months Ended | | through | ||
(in thousands, except share and per share data) |
|
| ||||
Net income attributable to common stockholders | | $ | i 20,576 |
| $ | i 23,581 |
| | | | | | |
Basic weighted average number of common shares outstanding | | | i 35,238,773 | | | i 35,228,894 |
Dilutive effect of stock-based awards | |
| i 2,828,598 | |
| i 2,751,475 |
Diluted weighted average number of common shares outstanding | |
| i 38,067,371 | |
| i 37,980,369 |
Basic net income per common share | | $ | i 0.58 | | $ | i 0.67 |
Diluted net income per common share | | $ | i 0.54 | | $ | i 0.62 |
The i 79,988 CFO RSUs and the i 223,220 RSUs outstanding during the Post-IPO period were not included in the calculation of diluted EPS as they were antidilutive. i 95,544 outstanding equity awards under the LTIP plan and the i 87,553 PSUs were not included in the calculation of dilutive EPS as the financial performance condition had not been met as of June 30, 2021.
Apria Healthcare Group had i i i i 992,719 / / / basic and diluted weighted average common shares outstanding for the period of January 1, 2021 through February 10, 2021 and the three and six months ended June 30, 2020.
i2. INTANGIBLE ASSETS
Intangible assets consist of the following:
i
| | | | | | | | | | | | | | | | | | | | |
|
|
| ||||||||||||||||||
| | Average | | Gross | | | | | | | | Gross | | | | | | | ||
| | Life in | | Carrying | | Accumulated | | Net Book | | Carrying | | Accumulated | | Net Book | ||||||
(dollars in thousands) |
| Years |
| Amount |
| Amortization |
| Value |
| Amount |
| Amortization |
| Value | ||||||
Intangible assets subject to amortization: | |
| | |
| | |
| | |
| | | |
| |||||
Capitated relationships | | 20.0 | | $ | i 4,400 | | $ | ( i 2,977) | | $ | i 1,423 | | $ | i 4,400 | | $ | ( i 2,880) | | $ | i 1,520 |
Payor relationships |
| 20.0 |
| | i 7,600 |
| | ( i 4,814) |
| | i 2,786 |
| | i 7,600 |
| | ( i 4,623) |
| | i 2,977 |
Subtotal |
| | | | i 12,000 |
| | ( i 7,791) |
| | i 4,209 |
| | i 12,000 |
| | ( i 7,503) |
| | i 4,497 |
Intangible assets not subject to amortization: |
| |
|
| |
|
| |
|
| |
|
| |
| |||||
Trade names |
| — |
| | i 50,000 |
| | — |
| | i 50,000 |
| | i 50,000 |
| | — |
| | i 50,000 |
Accreditations with commissions |
| — |
| | i 7,000 |
| | — |
| | i 7,000 |
| | i 7,000 |
| | — |
| | i 7,000 |
Subtotal |
| | | | i 57,000 |
| | — |
| | i 57,000 |
| | i 57,000 |
| | — |
| | i 57,000 |
Total | | | | $ | i 69,000 | | $ | ( i 7,791) | | $ | i 61,209 | | $ | i 69,000 | | $ | ( i 7,503) | | $ | i 61,497 |
Amortization expense was $ i i 0.1 / million for the three months ended June 30, 2021 and 2020, respectively, and $ i 0.9 million and $ i 0.3 million for the six months ended June 30, 2021 and 2020, respectively.
Estimated amortization expense for each of the fiscal years ending December 31 is presented below:
i
| | | |
(in thousands) |
|
| |
2021 (remainder) | | $ | i 287 |
2022 | |
| i 574 |
2023 | |
| i 574 |
2024 | |
| i 574 |
2025 | |
| i 574 |
Thereafter | |
| i 1,626 |
/17
i3. DEBT
Long-term debt consists of the following:
i
| | | | | | |
|
| June 30, | | December 31, | ||
(in thousands) |
| 2021 |
| 2020 | ||
Term Loan A | | $ | i 390,625 | | $ | i 401,042 |
Less: Current portion | |
| ( i 26,042) | |
| ( i 20,833) |
Less: Unamortized debt issuance costs | |
| ( i 3,306) | |
| ( i 3,820) |
Total long-term debt | | $ | i 361,277 | | $ | i 376,389 |
On June 21, 2019, Apria entered into a credit agreement with Citizens Bank and a syndicate of lenders for both a TLA of $ i 150.0 million and a Revolver of $ i 100.0 million. The Revolver replaced the prior Asset-Based Revolving Credit Facility which provided for revolving credit financing of up to $ i 125.0 million. Proceeds from the TLA were used to fund a $ i 175.0 million 2019 dividend payment to common stockholders and distribution to SARs holders.
On December 11, 2020, the Company entered into a credit facility amendment to obtain $ i 260.0 million of Incremental Term Loans. Net proceeds from the Incremental Term Loans were used to fund a $ i 200.3 million dividend payment to common stockholders and a $ i 9.7 million distribution to SARs holders declared and paid in December 2020, with the remaining proceeds used to pay fees and expenses in connection with the credit facility amendment and for general corporate purposes.
The credit agreement permits the interest rate to be selected at the Company’s option at either adjusted London Interbank Offered Rate (“Adjusted LIBOR”) or alternative base rate plus their respective applicable margin. Adjusted LIBOR is the rate for Eurodollar deposits for the applicable interest period while the alternate base rate is the highest of (i) the Administrative Agent’s “Prime Rate”, (ii) the Federal Funds Effective Rate plus i 0.50%, and (iii) one-month Adjusted LIBOR plus i 1.00%. Furthermore, Adjusted LIBOR is subject to a i 0.50% per annum floor and the alternative base rate is subject to a i 1.50% per annum floor. Additionally, the margin applied to both the TLA and Revolver is determined based on total net leverage ratio. Total net leverage ratio is defined as net debt, which represents indebtedness minus up to $ i 25.0 million in cash and cash equivalents over consolidated EBITDA as defined under the credit agreement. The following is a summary of the additional margin and commitment fees payable on both the TLA and available Revolver:
i
| | | | | | | | | | | |
|
| |
| Applicable | | Applicable | | |
| ||
| | | | Margin for | | Margin for | | |
| ||
| | | | Adjusted | | Alternative | | |
| ||
| | | | LIBOR | | Base Rate | | Commitment | |||
Level |
| Total Net Leverage Ratio |
| Loans | | Loans | | Fee | |||
I |
| Greater than or equal to 3.00x |
| i 2.75 | % | | i 1.75 | % | | i 0.35 | % |
II |
| Greater than or equal to 2.50x but less than 3.00x |
| i 2.50 | % | | i 1.50 | % | | i 0.30 | % |
III |
| Greater than or equal to 1.50x but less than 2.50x |
| i 2.25 | % | | i 1.25 | % | | i 0.25 | % |
IV |
| Less than 1.50x |
| i 2.00 | % | | i 1.00 | % | | i 0.20 | % |
The TLA matures on June 21, 2024 and the Company is required to make quarterly principal payments on the TLA beginning June 30, 2020. Upon entering into the credit facility amendment, the amount of those quarterly principal payments was adjusted to account for the Incremental Term Loans. The table below is a summary of the expected timing of remaining principal repayments each fiscal year:
i
| | | |
(in thousands) |
|
| |
2021 (remainder) | | $ | i 10,417 |
2022 | |
| i 36,458 |
2023 | |
| i 41,667 |
2024 | |
| i 302,083 |
/18
The credit agreement encompassing the TLA and Revolver permits the Company, subject to certain exceptions, to increase its TLA or its Revolver, as well as incur additional indebtedness, as long as it does not exceed the total net leverage ratio of i 3.00x. The credit agreement requires mandatory prepayments upon the occurrence of certain events, such as dispositions and casualty events, subject to certain exceptions. The TLA or Revolver may be voluntarily prepaid by the Company at any time without any premium or penalty.
The assets of the Company and equity interest of all present and future wholly-owned direct domestic subsidiaries, with certain exceptions, are pledged as collateral for the TLA and Revolver. The credit agreement contains a financial covenant requiring the Company to maintain a total net leverage ratio less than i 3.50x. The credit agreement also contains negative covenants that, among other things, restrict, subject to certain exceptions, the ability of Apria Healthcare Group and its restricted subsidiaries to incur additional indebtedness and guarantee indebtedness, create or incur liens, engage in mergers or consolidations, dispose of assets, pay dividends and distributions or repurchase capital stock, repay certain indebtedness, make investments and engage in certain transactions with affiliates.
As of June 30, 2021, there were $ i 15.8 million outstanding letters of credit, and additional availability under the Revolver net of letters of credit outstanding was $ i 84.2 million. The Company was in compliance with all debt covenants set forth in the TLA and Revolver as of June 30, 2021.
The Company records origination and other expenses related to certain debt issuance cost as a direct deduction from the carrying amount of the debt liability. These expenses are deferred and amortized using the straight-line method over the stated life, which approximates the effective interest rate method. Amortization of deferred debt issuance costs are classified within interest expense in the Company’s unaudited condensed consolidated statements of income and was $ i 0.2 million and $ i 0.1 million for the three months ended June 30, 2021 and 2020, respectively, and $ i 0.5 million and $ i 0.2 million for the six months ended June 30, 2021 and 2020, respectively.
Interest expense, excluding deferred debt issuance costs discussed above, was $ i 2.7 million and $ i 1.1 million for the three months ended June 30, 2021 and 2020, respectively, and $ i 5.4 million and $ i 2.7 million for the six months ended June 30, 2021 and 2020, respectively. The interest rate was i i 2.50 / % as of each of June 30, 2021 and December 31, 2020.
Interest paid on debt totaled $ i 2.7 million and $ i 1.1 million for the three months ended June 30, 2021 and 2020, respectively, and $ i 5.4 million and $ i 2.7 million for the six months ended June 30, 2021 and 2020, respectively.
i4. STOCK-BASED COMPENSATION
Profit Interest Units— On October 28, 2008, Apria Healthcare Group was acquired by a wholly-owned affiliate of BP Healthcare Holdings LLC (“Buyer”, or “BP Healthcare”). The Buyer was controlled by private investment funds affiliated with The Blackstone Group Inc. (the “Sponsor”). BP Healthcare and its subsidiary, Holdings, granted equity units to certain employees, Board members and a member of a subsidiary’s Board of Directors for purposes of retaining them and enabling such individuals to participate in the long-term growth and financial success of the Company. These equity awards were issued in exchange for services to be performed.
PIUs were composed of Class B and Class C units related to Holdings. Holdings also has i 3,575,000 outstanding in Class A-2 units, which are senior in liquidation rights to Class B units, whereas Class B units are senior in liquidation rights to Class C units. PIUs were measured at the grant date, based on the calculated fair value of the award, and were recognized as an expense over the employee’s requisite service period. There were no stated contractual lives for the units. The Company used the income approach and the guideline approach to estimate enterprise value, which was utilized to assess the fair value of each instrument.
Prior to the IPO, a portion of the Class B units vested over a specified period of time, generally i five years, and a portion of the outstanding performance Class B units vested as a result of a modification, which accelerated vesting. Also, prior to the IPO, all outstanding performance Class C units vested as all performance conditions were met.
In connection with the IPO, all outstanding PIUs were converted into shares of Apria, Inc. common stock based on the value of the units implied by the per share price of common stock sold in the IPO.
/19
The following table summarizes activity for all PIUs for the period from December 31, 2020 to February 10, 2021, the date at which they were all converted into shares of Apria, Inc. common stock:
i
| | | | | | | | | | |
|
| |
| Weighted- |
| |
| | Weighted- | |
| | | | Average | | | | | Average | |
| | | | Exercise | | Class C | | | Exercise | |
|
| Class B Units |
| Price |
| Units |
| | Price | |
Outstanding as of December 31, 2020 |
| i 88,008,850 | | $ | i 0.01 |
| i 2,849,092 |
| $ | — |
Converted |
| ( i 88,008,850) | |
| ( i 0.01) |
| ( i 2,849,092) |
|
| — |
Outstanding as of February 10, 2021 |
| — | | $ | — | | — |
| $ | — |
i i No / units were granted in 2021 or 2020, as PIUs are no longer granted. There was i no expense related to PIUs recorded in any period presented.
Stock Appreciation Rights—In 2015, the Company’s Board of Directors approved the Apria, Inc. 2015 Stock Plan that provided for the grant of stock appreciation rights to directors, officers, employees, consultants and advisers (and prospective directors, officers, employees, consultants, and advisers) of the Company and its affiliates. These equity awards were issued in exchange for services to be performed.
The plan mandated a maximum award term of i 10 years and that SARs be granted with a strike price not less than the fair market value determined as of the date of grant. SARs are measured at the grant date, based on the calculated fair value of the award and are recognized as an expense over the employee’s requisite service period. SARs granted under the plan generally vest over i 60 months from the date of grant based on continued service. The contractual lives for the units are i 10 years. All unvested SARs are forfeited upon employee termination. The Company accounts for forfeitures when they occur, and ultimately stock-based compensation is only recognized for awards that vest. In the event of a change in capital structure or similar event, SARs may be modified.
In connection with the IPO, Apria Healthcare Group SARs were converted to Apria, Inc. SARs at a conversion ratio based on the value of the units implied by the per share price of common stock sold in the IPO. Further, a pre-existing provision in the SARs was triggered, under which the SARs became exercisable by the holders.
Expense related to SARs held by holders continuing to perform services for the Company is recorded within SD&A expenses in the unaudited condensed consolidated statements of income and was $ i 0.4 million and $ i 0.5 million for the three months ended June 30, 2021 and 2020, respectively, and $ i i 0.9 / million for the six months ended June 30, 2021 and 2020. As of June 30, 2021, total unrecognized compensation cost related to unvested SARs was $ i 4.0 million, which is expected to be expensed over a weighted-average period of i 3.1 years.
iThe following table summarizes activity for all SARs for the period from December 31, 2020 to June 30, 2021:
| | | | | | | | | | |
|
| |
| | |
| Weighted- |
| | |
| | | | Weighted- | | Average | | | Aggregate | |
| | Stock | | Average | | Remaining | | | Intrinsic | |
| | Appreciation | | Exercise | | Contractual | | | Value | |
|
| Rights |
| Price |
| Term |
| | ($000s) | |
Outstanding as of December 31, 2020 |
| i 106,113 | | $ | i 220.42 |
| i 7.0 |
| $ | i 51,885 |
Converted (1) |
| i 3,660,115 | |
| |
|
|
|
| |
Exercised | | ( i 109,746) | | | i 6.99 | | | | | |
Forfeited | | ( i 15,188) | | | i 5.33 | | | | | |
Outstanding as of June 30, 2021 |
| i 3,641,294 | | $ | i 6.20 |
| i 6.5 | | $ | i 101,956 |
Vested units as of June 30, 2021 |
| i 2,389,985 | |
|
|
|
| |
|
|
Exercisable as of June 30, 2021 | | i 2,351,014 | | $ | i 6.94 | | i 5.6 | | $ | i 65,828 |
| (1) | Represents the incremental SARs outstanding as a result of the conversion of Apria Healthcare Group SARs into Apria, Inc. SARs in connection with the IPO. |
20
The total intrinsic value exercised during the six months ended June 30, 2021 was $ i 3.4 million.
The following table summarizes the activity for unvested shares for the period from December 31, 2020 to June 30, 2021:
i
| | | | | |
|
| |
| Weighted- | |
| | Stock | | Average | |
| | Appreciation | | Grant-Date | |
|
| Rights |
| Fair Value | |
Unvested as of December 31, 2020 |
| i 45,266 | | $ | i 119.46 |
Converted (1) |
| i 1,561,343 | |
| |
Vested |
| ( i 340,112) | |
| i 3.46 |
Forfeited |
| ( i 15,188) | |
| i 3.26 |
Unvested as of June 30, 2021 |
| i 1,251,309 | | $ | i 3.34 |
| (1) | Represents the incremental SARs outstanding as a result of the conversion of Apria Healthcare Group SARs into Apria, Inc. SARs in connection with the IPO. |
There were i 20,407 SARs granted in the six months ended June 30, 2020. As of June 30, 2021, there were i no SARs available for future grants under the plan as no new equity-based awards will be granted under the Apria, Inc. 2015 Stock Plan.
Omnibus Plan Awards—The Company granted RSUs and PSUs, under the 2021 Omnibus Incentive Plan, or collectively referred to as Omnibus Plan Awards. The Omnibus Plan Awards vest either based solely on the satisfaction of time-based service conditions or on the satisfaction of time-based service conditions combined with a performance criterion. Omnibus Plan Awards are subject to forfeiture if the holder’s services to the Company terminate before vesting.
Omnibus Plan Awards with only time-based service vesting conditions granted to non-employee directors vest on the earlier of (i) the first anniversary of the vesting commencement date, and (ii) the first regularly scheduled annual meeting of the stockholders of the Company following the date of grant. Omnibus Plan Awards with only time-based service vesting conditions granted to employees vest over a i three-year service period, as defined in the terms of each award. Omnibus Plan Awards that vest based on the satisfaction of a time-based service conditions combined with a performance criterion generally vest at the end of a two-and-a-half-year service period and i three-year performance period, based on performance criteria established at the time of the award. The portion of the Omnibus Plan Award that is earned may be i zero to i 200% of the targeted number of shares subject to the Omnibus Plan Award depending on whether the performance criterion is met or exceeded.
i
| | | | | | | | | | | |
| | Time-Based | | Time-Based | | Performance | | | | Weighted-Average | |
Omnibus Plan Awards | | One Year Vesting | | Three Year Vesting | | and Time-Based | | Total | | Grant Date Fair Value | |
Unvested Omnibus Plan Awards at December 31, 2020 | | — | | — | | — | | — | | $ | — |
Granted (1) | | i 35,413 | | i 197,807 | | i 87,553 | | i 320,773 | | | i 29.65 |
Unvested Omnibus Plan Awards at June 30, 2021(1) | | i 35,413 | | i 197,807 | | i 87,553 | | i 320,773 | | $ | i 29.65 |
Unvested Omnibus Plan Awards expected to vest as of June 30, 2021 | | | | | | | | i 320,773 | | $ | i 29.65 |
| (1) | Granted Omnibus Plan Awards and unvested Omnibus Plan Awards presented are based on the payout of the targeted number of shares. |
Expense related to Omnibus Plan Awards is recorded within SD&A expenses in the unaudited condensed consolidated statement of income and was $ i i 0.6 / million for the three and six months ended June 30, 2021. As of June 30,
21
2021, the unrecognized compensation cost related to unvested Omnibus Plan Awards was $ i 8.9 million, excluding estimated forfeitures. This amount is expected to be recognized over a weighted-average period of i 2.6 years. The Company accounts for forfeitures when they occur, and ultimately stock-based compensation expense is only recognized for awards that vest.
CFO Restricted Stock Units—The offering resulted in the grant of RSUs to the Company’s CFO. The RSUs vest in tranches, with the first tranche vesting immediately upon the completion of the offering and the remaining RSUs vesting in i two equal tranches upon the i six month and i one-year anniversary following the offering, subject to the CFO’s continued employment. Each tranche of RSUs can be settled in either cash or shares of the Company’s common stock at the election of the CFO.
The first tranche of RSUs vested upon completion of the IPO and was settled in cash. The remaining RSUs are settleable in cash or shares at the CFO’s election, which is outside of the control of the Company. As such, the remaining RSUs were treated as liability classified awards. The fair value was measured at the grant date and will be remeasured each reporting period until settlement. Compensation expense is recognized over the requisite service period subject to continued employment and adjusted each reporting period for changes in the fair value pro-rated for the portion of the requisite service period rendered. Expense related to RSUs is recorded within SD&A expenses in the unaudited condensed consolidated statement of income and was $ i 0.6 million and $ i 2.4 million for the three and six months ended June 30, 2021, respectively. As of June 30, 2021, $ i 0.8 million was recorded within other accrued liabilities in the unaudited condensed consolidated balance sheet. Total unrecognized compensation cost related to RSUs was $ i 1.4 million as of June 30, 2021. This amount is expected to be recognized over a weighted-average period of i 0.6 years.
The following table summarizes activity for CFO RSUs for the period from December 31, 2020 to June 30, 2021:
i
| | | | | |
|
| Restricted |
| Weighted-Average | |
| | Stock | | Grant-Date | |
| | Units | | Fair Value | |
Balance as of December 31, 2020 | | — | | $ | — |
Granted at IPO | | i 159,976 | | | i 20.00 |
Vested and paid at IPO | | ( i 79,988) | | | i 20.00 |
Unvested and outstanding as of June 30, 2021 | | i 79,988 | | $ | i 20.00 |
Long-Term Incentive Plan—The Company has a long-term cash incentive plan to incentivize free cash flow improvement and the transformational changes needed to position the Company properly for the future. The Company has awarded long-term incentive awards to executive officers and other key management employees.
The offering triggered a pre-existing provision under the Company’s 2019 LTIP pursuant to which the incentive awards will be settled in shares of the Company’s common stock. The maximum number of shares to be issued was determined by dividing the amount of each executive’s earned award by the volume-weighted average price of a share of common stock over the first i 20 trading days following the offering. Awards granted under the 2019 LTIP have a maximum share count of i 193,350 as of June 30, 2021. The offering was accounted for as a modification and, as such, the 2019 LTIP awards were reclassified from a liability to an equity classified award in connection with the IPO. As such, the estimated plan liability for services rendered during the term of the awards of $ i 2.2 million, which was recorded within other noncurrent liabilities in the audited consolidated balance sheet as of December 31, 2020, was reclassed to additional paid-in capital in the unaudited condensed consolidated financial statements as of June 30, 2021.
Expense related to the LTIP is recorded within SD&A expenses in the unaudited condensed consolidated statements of income and was $ i 0.3 million and $ i 0.2 million in the three months ended June 30, 2021 and 2020, respectively, and $ i 0.7 million and $ i 0.3 million for the six months ended June 30, 2021 and 2020, respectively. As of June 30, 2021, total estimated unrecognized compensation cost related to the LTIP was $ i 1.4 million. This amount is expected to be recognized over a weighted-average period of i 1.3 years.
22
The following table summarizes maximum share count activity under LTIP awards for the period from December 31, 2020 to June 30, 2021 as it is probable that the Company will achieve the maximum free cash flow payout level under the plan:
i
| | | | | |
|
| |
| Weighted- | |
| | Long-Term | | Average | |
| | Incentive | | Grant-Date | |
| | Plan | | Fair Value | |
Balance as of December 31, 2020 | | — | | $ | — |
Conversion at IPO | | i 199,004 | | | i 22.11 |
Forfeited | | ( i 5,654) | | | i 22.11 |
Balance as of June 30, 2021 | | i 193,350 | | $ | i 22.11 |
i5. INCOME TAXES
The Company’s effective tax rate was i 29.9% for the three months ended June 30, 2021 compared to i 33.0% for the three months ended June 30, 2020. The Company’s effective tax rate was i 33.0% for the six months ended June 30, 2021 compared to i 30.5% for the six months ended June 30, 2020.
For the six months ended June 30, 2021, the Company’s effective tax rate differed from federal and state statutory rates primarily due to non-deductible executive compensation and non-deductible public offering costs. For the six months ended June 30, 2020, the Company’s effective tax rate differed from federal and state statutory rates primarily due to non-deductible expenses for tax purposes.
Deferred income taxes arise from temporary differences between the carrying amounts of assets and liabilities for tax and financial reporting purposes and tax losses and credit carryforwards. Deferred income tax assets are required to be reduced by a valuation allowance when it is determined that it is more likely than not that all or a portion of a deferred tax asset will not be realized.
As of each reporting date, management considers new evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets. As of June 30, 2021, management evaluated all positive and negative evidence related to its valuation allowance, including its three years of cumulative pretax income and its projected income, and determined that there is sufficient positive evidence to conclude that it is more likely than not that net deferred taxes of $ i 6.7 million and $ i 18.3 million as of June 30, 2021 and December 31, 2020, respectively, are realizable.
The Company accounts for its tax uncertainties under GAAP. For the six months ended June 30, 2021, no material changes occurred with respect to the Company’s tax uncertainties that would require disclosure.
The Company does not expect any material changes to its tax uncertainties within the 12-month rolling period ending June 30, 2022.
Net income tax payments were $ i 1.4 million and $ i 0.2 million for the three months ended June 30, 2021 and 2020, respectively, and $ i 2.0 million and $ i 0.3 million for the six months ended June 30, 2021 and 2020, respectively.
/
i6. LEASES
The Company leases all its facilities. The Company’s real estate lease portfolio primarily consists of modified gross leases, in which the Company pays a share of the operating costs, and triple-net leases, in which the Company pays all of the operating costs. Operating costs that are the responsibility of the Company include taxes, maintenance, insurance and other allowable expenses. These expenses are considered variable costs as they are not tied to an index or rate. In addition, delivery vehicles and office equipment are leased under operating leases. Lease terms are generally i five years or less with i renewal options for additional periods and often contain early termination clauses. Rents are generally
/23
increased annually by amounts stated within individual agreements, subject to certain maximum amounts defined within individual agreements.
The Company also leases certain patient equipment. Lease terms are generally i twelve months or less with renewal options for additional periods. The Company also has short-term patient equipment leases with certain suppliers that are entirely variable based on equipment usage or a percentage of net revenues collected for specific products. Patient equipment lease expense is recorded in product and supply costs in the unaudited condensed consolidated statements of income in the period incurred. The Company uses the portfolio approach to review patient equipment leases.
All of the Company’s leases are classified as operating leases. The leases do not include options to purchase the underlying assets that the Company is reasonably certain to exercise. The components of lease assets and liabilities are included on the unaudited condensed consolidated balance sheets.
Significant components of lease expense were:
i
| | | | | | | | | | | | |
|
| Three Months Ended | | Six Months Ended | ||||||||
| | June 30, | | June 30, | ||||||||
(in thousands) | | 2021 | | 2020 |
| 2021 |
| 2020 | ||||
Operating lease expense | | $ | i 8,616 | | $ | i 9,129 | | $ | i 17,766 | | $ | i 18,655 |
Variable lease expense | |
| i 6,105 | |
| i 5,291 | |
| i 11,989 | |
| i 11,320 |
Short-term lease expense | |
| i 544 | |
| i 293 | |
| i 1,046 | |
| i 525 |
Total lease expense | | $ | i 15,265 | | $ | i 14,713 | | $ | i 30,801 | | $ | i 30,500 |
The following table summarizes supplemental information related to the Company’s operating leases:
i
| | | | | | | | | | | | | |
|
| Three Months Ended | | Six Months Ended | | ||||||||
| | June 30, | | June 30, | | ||||||||
(dollars in thousands) | | 2021 |
| 2020 | | 2021 |
| 2020 | | ||||
Cash paid for amounts included in the measurement of operating lease liabilities | | $ | i 7,073 | | $ | i 5,720 | | $ | i 14,653 | | $ | i 14,042 | |
Right-of-use assets obtained in exchange for new operating lease liabilities | | | i 8,414 | | | i 1,101 | | | i 14,009 | | | i 8,874 | |
Weighted average remaining lease term | | | i 3.1 years | | | i 3.0 years | | | i 3.1 years | | | i 3.0 years | |
Weighted average discount rate | | | i 4.0 | % | | i 5.2 | % | | i 4.0 | % | | i 5.2 | % |
i7. COMMITMENTS AND CONTINGENCIES
Litigation—On December 18, 2020, a federal judge approved a civil and administrative settlement Apria entered into with the United States and state Medicaid programs in a complaint filed by i three relators under the qui tam provisions of the False Claims Act (“FCA”), 31 U.S.C. § 3729 et seq., as well as comparable state false claims laws, in connection with the rental of non-invasive ventilators (“NIVs”). Apria also entered into separate settlements to resolve the relators’ claims brought on behalf of the States of California and Illinois related to NIVs covered by private insurers. The matter had been pending since 2017.
The government had alleged that Apria violated the FCA by submitting false claims seeking reimbursement for NIVs which were not being used, or not being used sufficiently, by patients, for NIVs which were being used pursuant to physician orders on a device setting which was available from other less expensive devices, and for improperly waiving co-pays to induce beneficiaries to rent NIVs. To resolve any potential liability, Apria agreed to enter into a civil settlement agreement with the government and paid $ i 40.0 million to the federal government and the states during the year ended December 31, 2020. Apria separately agreed with the relators and paid approximately $ i 3.6 million during the year ended December 31, 2020 to settle all remaining claims from their complaint, including: (1) claims for retaliation in violation of federal and state laws; (2) claims for attorneys’ fees and costs available under federal and state law; and (3) claims under the Illinois Insurance Claims Fraud Prevention Act, 740 ILL. COMP. STAT. 92/1 et seq. Apria also agreed with the California Department of Insurance to pay $ i 0.5 million, which was paid during the three months ended March 31, 2021, to resolve claims asserted by the relators under the California Insurance Frauds Prevention Act, CAL.
/24
INS. CODE § 1871 et seq. Apria did not admit that any of its conduct was illegal or otherwise improper. The expense is included in SD&A expenses in the unaudited condensed consolidated statements of income and was $ i 0.0 million and $ i 10.8 million for the three months ended June 30, 2021 and 2020, respectively, and $ i 0.0 million and $ i 12.8 million for the six months ended June 30, 2021 and 2020, respectively.
In addition to the matter referenced in this note, the Company is engaged in the defense of certain claims and lawsuits arising out of the ordinary course and conduct of its business, the outcomes of which are not determinable at this time. Insurance policies covering such potential losses, where such coverage is cost effective, are maintained. In the opinion of management, any liability that might be incurred upon the resolution of these claims and lawsuits will not, in the aggregate, have a material effect on the Company’s financial condition or results of operations, cash flows and liquidity.
Supplier Concentration—Approximately i 76% of purchases for patient equipment and supplies are from i five vendors. Although there are a limited number of suppliers, management believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery and possible losses of revenue, which could adversely affect the Company’s consolidated financial condition or operating results. In June 2021, one of our suppliers, Philips Respironics, announced a voluntary recall for continuous and non-continuous ventilators (certain CPAP, BiLevel positive airway pressure and ventilator devices) related to polyurethane foam used in those devices. The Food and Drug Administration (“FDA”) has since identified this as a Class I recall, the most serious category of recall. There was no expense related to the recall recorded in the six months ended June 30, 2021. In addition, from time to time, the Company enters into exclusive arrangements with certain suppliers to provide patient equipment and supplies.
Purchase Obligations—In April 2009, the Company entered into a i ten-year information technology services agreement to outsource certain information systems functions. Effective February 2020, the agreement was amended a second time to extend the agreement through January 2024. If the Company terminated the agreement, the required obligation to the vendor would be approximately $ i 4.5 million for services during the 120-day cancellation notice period plus termination fees.
Guarantees and Indemnities—From time to time, the Company enters into certain types of contracts that contingently require the Company to indemnify parties against third-party claims. These contracts primarily relate to: (i) certain asset purchase agreements, under which the Company may provide customary indemnification to the seller of the business being acquired; (ii) certain real estate leases, under which the Company may be required to indemnify property owners for environmental and other liabilities, and other claims arising from the Company’s use of the applicable premises; and (iii) certain agreements with the Company’s officers, directors, and employees, under which the Company may be required to indemnify such persons for liabilities arising out of their relationship with the Company.
The terms of such obligations vary by contract, and in most instances, a specific or maximum dollar amount is not explicitly stated therein. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, no liabilities have been recorded for these obligations on the unaudited condensed consolidated balance sheets for any of the periods presented.
i8. CERTAIN RELATIONSHIPS AND RELATED-PARTY TRANSACTIONS
Change Healthcare— In December 1999, the Company entered into an agreement with Change Healthcare, a company affiliated with the Sponsor since 2011, to perform various revenue and payment cycle management functions. The Company paid Change Healthcare approximately $ i 0.9 million and $ i 0.7 million for the three months ended June 30, 2021 and 2020, respectively, and $ i 1.4 million and $ i 1.5 million for the six months ended June 30, 2021 and 2020, respectively. Amounts included in accounts payable were $ i 0.5 million and $ i 0.2 million as of June 30, 2021 and December 31, 2020, respectively.
BREIT Industrial Canyon PA1W01 LLC—In May 2018, the Company began paying BREIT Industrial Canyon, a subsidiary of Blackstone Real Estate Income Trust, Inc., which is a non-exchange traded, perpetual life real estate investment trust externally managed by an affiliate of the Sponsor, which had acquired a property for which the Company is in a lease agreement through October 2023. The Company paid BREIT Industrial Canyon approximately
/25
$ i 0.4 million and $ i 0.2 million for the three months ended June 30, 2021 and 2020, respectively, and $ i 0.6 million and $ i 0.3 million for the six months ended June 30, 2021 and 2020, respectively. The discounted operating lease liability for the remaining noncancelable lease term is $ i 1.5 million and $ i 1.7 million as of June 30, 2021 and December 31, 2020, respectively.
Mphasis—In September 2019, the Company entered into an i 87-month agreement with Mphasis, a Company affiliated with the Sponsor since 2016, to perform various technology related services previously performed by another outsource vendor. The Company has the right to terminate for convenience with a minimum i three-month notice. If the Company terminated the agreement, the required obligation to the vendor would be approximately $ i 1.1 million for services during the i three-month cancellation notice period. The Company paid Mphasis approximately $ i 1.5 million and $ i 1.7 million for the three months ended June 30, 2021 and 2020, respectively, and $ i 2.6 million and $ i 1.7 million for the six months ended June 30, 2021 and 2020, respectively. Amounts included in accounts payable were $ i 0.8 million and $ i 0.4 million as of June 30, 2021 and December 31, 2020, respectively.
Alight Solutions—In December 2019, the Company entered into an agreement with Alight Solutions, a Company affiliated with the Sponsor since 2017, to perform services related to the deployment of a new financial management system. The Company also entered into a i three-year post-implementation support contract that is expected to begin prior to the end of 2021. The Company paid Alight approximately $ i 0.3 for the three months ended June 30, 2021 and 2020, respectively, and $ i 0.7 million and $ i 0.3 million for the six months ended June 30, 2021 and 2020, respectively. Amounts included in accounts payable were $ i 0.4 million and $ i 0.3 million as of June 30, 2021 and December 31, 2020, respectively.
Blue Yonder— Blue Yonder provides software solutions for supply chain planning optimization. The Company paid Blue Yonder, a Company affiliated with the Sponsor, approximately $ i 0.0 million for the three months ended June 30, 2021 and 2020, and $ i 0.0 million and $ i 0.5 million for the six months ended June 30, 2021 and 2020, respectively. i i No / amounts were included in accounts payable as of June 30, 2021 and December 31, 2020.
i9. SUBSEQUENT EVENT
On July 30, 2021, Apria Healthcare LLC, a wholly owned subsidiary of the Company, and Airway Breathing Co., a Virginia corporation (“ABC”), entered into a definitive asset purchase agreement whereby the Company will acquire certain assets of ABC. ABC provides services and products in the home respiratory therapy/home medical equipment segment and provides the Company with a market expansion opportunity. This transaction is expected to close during the three months ended September 30, 2021.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis of Apria, Inc. (the “Company,” “our,” or “we”) and its subsidiaries financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes thereto included elsewhere in this report and with our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (the “2020 Form 10-K”). In addition to historical information, this discussion contains forward-looking statements that involve risks, uncertainties and assumptions that could cause actual results to differ materially from management’s expectations. Certain factors that could cause such differences are discussed in Part I, Item 1A. “Risk Factors” in the 2020 Form 10-K, Part II, Item 1A. “Risk Factors” in this report, and “Cautionary Note Regarding Forward-Looking Statements” in this report.
We are a leading provider of integrated home healthcare equipment and related services in the United States. We offer a comprehensive range of products and services for in-home care and delivery across three core service lines: (1) home respiratory therapy (including home oxygen and non-invasive ventilation (“NIV”) services); (2) obstructive sleep apnea (“OSA”) treatment (including continuous positive airway pressure (“CPAP”) and bi-level positive airway pressure devices, and patient support services); and (3) negative pressure wound therapy (“NPWT”). Additionally, we supply a wide range of home medical equipment and other products and services to help improve the quality of life for patients with home care needs. Our revenues are generated through fee-for-service and capitation arrangements with
26
third-party healthcare payors, including government and commercial payors (“Payors”) for equipment, supplies, services and other items we rent or sell to patients. Through our offerings, we also provide patients with a variety of clinical and administrative support services and related products and supplies, most of which are prescribed by a physician as part of a care plan.
In 2020, we served nearly 2 million patients, made approximately 2.4 million deliveries and conducted approximately 735,000 clinician interactions with our patients.
Impact of COVID-19 Pandemic
Our priorities during the novel coronavirus (“COVID-19”) pandemic are protecting the health and safety of our employees (including patient-facing employees providing respiratory and other services), maximizing the availability of our services and products to support patient health needs, and the operational and financial stability of our business.
In response to the COVID-19 pandemic and the National Emergency Declaration, dated March 13, 2020, we activated certain business interruption protocols, including acquisition and distribution of personal protective equipment (“PPE”) to our patient-facing employees, accelerated capital expenditures of certain products and relocation of significant portions of our workforce to “work-from-home” status.
While the impact of the COVID-19 pandemic, the National Emergency Declaration and the various state and local government imposed stay-at-home restrictions did not have a material adverse impact on our consolidated operating results for the six months ended June 30, 2021 and the fiscal year ended December 31, 2020, we experienced declines in net revenues in certain services associated with elective medical procedures and the disruption in physician practices (such as commencement of new CPAP services, ventilation therapy, negative pressure wound therapy, and other equipment and services) and such declines may continue during the duration of the COVID-19 pandemic. Offsetting these declines in net revenue, we have experienced an increase in net revenue related to increased demand for certain respiratory products (such as oxygen) and increased sales in our resupply business (primarily as a result of the increased ability to contact patients at home as a result of state and local government imposed stay-at-home orders). In response, we instituted temporary cost mitigation measures such as reduced hours and management of variable labor and operating costs. In addition, as part of the Coronavirus Aid, Relief and Economic Security (“CARES”) Act, we experienced an increase in Medicare reimbursement rates from March 6, 2020 to the end of the public health emergency and a suspension of Medicare sequestration from May 1, 2020 through December 31, 2021 (resulting in a 2% increase in Medicare payments to all providers) resulting in a temporary increase in net revenues for certain products and services.
Recent regulatory guidance from the Centers for Medicare and Medicaid Services expanding telemedicine and reducing documentation requirements during the emergency period resulted in increased net revenues for certain products and services. We have not experienced a significant slowdown in cash collections, and as a result our cash flow from operations has not been materially adversely impacted to date.
In 2021, the global economy has, with certain setbacks, begun reopening, and wider distribution of vaccines will likely encourage greater economic activity. Nevertheless, we are unable to predict how widely utilized the vaccines will be, whether they will be effective in preventing the spread of COVID-19 (including its variant strains), and when or if normal economic activity and business operations will fully resume. We are closely monitoring the impact of the COVID-19 pandemic, including the emergence of variant strains of the virus, on our business. It is difficult to predict the future impact COVID-19 may have on our business, results of operations, financial position and cash flows.
Impact of Philips Respironics Recall
In June 2021, one of our suppliers, Philips Respironics, announced a voluntary recall for continuous and non-continuous ventilators (certain CPAP, BiLevel positive airway pressure and ventilator devices) related to polyurethane foam used in those devices. The Food and Drug Administration (“FDA”) has since identified this as a Class I recall, the most serious category of recall. Because we distribute these products and provide related home respiratory services and, in part, due to the substantial number of impacted devices, our management team has devoted, and will likely continue to devote, substantial time and resources to coordinating recall-related activity and to supporting our home healthcare
27
patients’ needs. This recall may cause us to incur significant costs, some or all of which may not be recoverable from the product manufacturer. The recall may also materially negatively affect our revenues and results of operations as a result of patients not using their impacted devices, current shortages in the availability of both replacement devices for impacted patients and new devices for new patients, patient hesitancy to use respiratory devices generally or other reasons.
We are closely monitoring the impact of the recall on our business and the uncertainty surrounding the availability and supply of CPAP and ventilators due to the recall. While the recall did not have a material adverse impact on our consolidated operating results for the six months ended June 30, 2021, there is an equipment shortage building and the recall or other potential supply chain disruptions may have a future material adverse effect on our financial condition or results of operations, cash flows and liquidity. See Part II, Item 1A. “Risk Factors” in this report.
Components of Operating Results
Net Revenues. Revenues are recognized under fee-for-service and capitation arrangements for equipment, supplies, services and other items we rent or sell to patients. Fee-for-service is a payment model where we are paid for our service to provide equipment, supplies and other items. Capitation is a payment arrangement where a set amount is paid per member per month for a defined patient population, based on a negotiated contractual rate derived using average expected utilization of services.
Revenue generated from equipment that we rent to patients is recognized over the noncancelable rental period and commences on delivery of the equipment to the patients. Revenue related to sales of equipment and supplies is recognized on the date of delivery to the patients. Capitation revenue is recognized as a result of entering into a contract with a third party to stand ready to provide its members certain services without regard to the actual services provided; therefore, revenue is recognized over the period that the beneficiaries are entitled to healthcare services. Due to the nature of our industry and the reimbursement environment in which we operate, certain estimates are required to record total net revenues.
Cost of Net Revenues and Gross Margin.
Cost of Net Revenues. We incur product and supply costs, depreciation of patient equipment, home respiratory therapists costs and other costs in connection with providing our services:
| ● | Product and supply costs are comprised primarily of the cost of supplies, equipment and accessories provided to patients. |
| ● | Patient equipment depreciation is provided using the straight-line method over the estimated useful lives of the equipment, which range from 1 to 10 years. Patient equipment depreciation is classified in our unaudited condensed consolidated statements of income within cost of net revenues as the equipment is rented to patients as part of our primary operations. Patient equipment is generally placed for rent; however, it could also be sold to customers. Upon a sale, we record the proceeds of the sale within net revenue and the cost related to the carrying net book value as other costs within cost of net revenues in our unaudited condensed consolidated statements of income. |
| ● | Home respiratory therapists costs are comprised primarily of employee salary and benefit costs or contract fees paid to respiratory therapists and other related professionals who are deployed to service a patient. |
Gross Margin. Gross margin is gross profit expressed as a percentage of net revenues. Our gross margin is impacted by Payor and product mix, fluctuations in pricing of supplies, equipment and accessories, as well as changes in reimbursement rates.
28
Selling, Distribution and Administrative. Selling, distribution and administrative (“SD&A”) expenses are comprised of expenses incurred in support of our operations and administrative functions and includes labor costs, such as salaries, bonuses, commissions, benefits and travel-related expenses for our employees, facilities rental costs, third-party revenue cycle management costs and corporate support costs including finance, information technology, legal, human resources, procurement, and other administrative costs. Distribution expenses represents the cost incurred to coordinate and deliver products and services to the patients. Included in distribution expenses are leasing, maintenance, licensing and fuel costs for the vehicle fleet; salaries, benefits and other costs related to drivers and dispatch personnel; and amounts paid to couriers and other third-party logistics and shipping vendors.
Income Tax Expense. Our provision for income taxes is based on expected income, permanent book/tax differences and statutory tax rates in the various jurisdictions in which we operate. Significant estimates and judgments are required in determining the provision for income taxes.
Seasonality
Our business is sensitive to seasonal fluctuations. Our patients are generally responsible for a greater percentage of the cost of their treatment or therapy during the early months of the year due to co-insurance, co-payments and deductibles, and therefore may defer treatment and services of certain therapies until meeting their annual deductibles. In addition, changes to employer insurance coverage often go into effect at the beginning of each calendar year which may impact eligibility requirements and delay or defer treatment or recognition of revenues. These factors may lead to lower total revenues and cash flow in the early part of the year and higher total revenues and cash flow in the latter half of the year. Additionally, the increased incidence of respiratory infections during the winter season may result in initiation of additional respiratory services such as oxygen therapy for certain patient populations. Our quarterly operating results may fluctuate significantly in the future depending on these and other factors.
Key Performance Metrics
We regularly review key performance metrics to evaluate our business, measure our performance, identify trends in our business, prepare financial projections and make strategic decisions.
EBITDA, Adjusted EBITDA and Adjusted EBITDA less Patient Equipment Capex. We use the non-GAAP financial information of earnings, before interest, taxes, depreciation, and amortization (“EBITDA”), Adjusted EBITDA and Adjusted EBITDA less Patient Equipment Capex as key profitability measures to evaluate the business. Refer to the “Non-GAAP financial information” section below for further detail, including a table reconciling each of such measures to net income, the most directly comparable accounting principles generally accepted in the United States of America (“GAAP”) measure. The below table sets forth net income, EBITDA, Adjusted EBITDA and Adjusted EBITDA less Patient Equipment Capex for each of the three and six months ended June 30, 2021 and 2020:
| | | | | | | | | | | | |
| | Three Months Ended June 30, | | Six Months Ended June 30, | ||||||||
(in thousands) |
| 2021 |
| 2020 |
| 2021 |
| 2020 | ||||
Net income | | $ | 20,576 | | $ | 8,129 | | $ | 25,120 | | $ | 14,568 |
EBITDA | | $ | 61,228 | | $ | 42,826 | | $ | 101,909 | | $ | 81,702 |
Adjusted EBITDA | | $ | 64,351 | | $ | 55,721 | | $ | 112,626 | | $ | 97,770 |
Adjusted EBITDA less Patient Equipment Capex | | $ | 44,101 | | $ | 43,133 | | $ | 68,844 | | $ | 60,713 |
29
Results of Operations
Comparison of Three Months Ended June 30, 2021 and Three Months Ended June 30, 2020.
The following table summarizes our consolidated results of operations:
| | | | | | | | | | | | |
| | Three Months Ended June 30, | | | | | |
| ||||
(dollar amounts in thousands) |
| 2021 |
| 2020 |
| Change $ |
| Change % | ||||
Net revenues | | $ | 286,279 | | $ | 268,942 | | $ | 17,337 |
| 6.4 | % |
Cost of net revenues, including related depreciation | |
| 84,748 | |
| 80,867 | |
| 3,881 |
| 4.8 | % |
Gross margin | |
| 201,531 | |
| 188,075 | |
| 13,456 |
| 7.2 | % |
Selling, distribution and administrative | |
| 169,275 | |
| 174,793 | |
| (5,518) |
| (3.2) | % |
Total costs and expenses | |
| 254,023 | |
| 255,660 | |
| (1,637) |
| (0.6) | % |
Operating income | |
| 32,256 | |
| 13,282 | |
| 18,974 |
| 142.9 | % |
Interest expense | |
| 2,928 | |
| 1,243 | |
| 1,685 |
| 135.6 | % |
Interest income | |
| (36) | |
| (87) | |
| 51 |
| (58.6) | % |
Income tax expense | |
| 8,788 | |
| 3,997 | |
| 4,791 |
| 119.9 | % |
Net income | | $ | 20,576 | | $ | 8,129 | | $ | 12,447 |
| 153.1 | % |
Net Revenues. Net revenues for the three months ended June 30, 2021 were $286.3 million compared to $268.9 million for the three months ended June 30, 2020, an increase of $17.3 million or 6.4%. The increase in net revenues for the three months ended June 30, 2021 was primarily due to growth in OSA treatment and home respiratory therapy. The increase was partially offset by lower ventilation therapy revenues due to a reduction in the commencement of new services during the COVID-19 pandemic. The increase in net revenues was also due to higher reimbursement levels and increased Medicare reimbursement rates from oxygen budget neutrality, the CARES Act and the temporary suspension of Medicare sequestration, partially offset by reductions in commercial Payor reimbursement rates. Our core services comprise total net revenues as follows:
| | | | | | | | | | | | |
|
| Three Months Ended June 30, |
|
| |
|
|
| ||||
(dollar amounts in thousands) |
| 2021 |
| 2020 |
| Change $ |
| Change % | ||||
Home respiratory therapy | | $ | 116,005 | | $ | 111,531 | | $ | 4,474 |
| 4.0 | % |
OSA treatment | |
| 121,479 | |
| 109,649 | |
| 11,830 |
| 10.8 | % |
NPWT | |
| 10,273 | |
| 9,631 | |
| 642 |
| 6.7 | % |
Other equipment and services | |
| 38,522 | |
| 38,131 | |
| 391 |
| 1.0 | % |
Net revenues | | $ | 286,279 | | $ | 268,942 | | $ | 17,337 |
| 6.4 | % |
Net revenues for the three months ended June 30, 2021 increased primarily due to the following:
| ● | Home respiratory therapy. Net revenues increased 4.0% primarily due to increased volume of patients requiring oxygen therapy, higher reimbursement levels and increased Medicare reimbursement rates from oxygen budget neutrality, the CARES Act, and the temporary suspension of Medicare sequestration. The increase was partially offset by lower ventilation therapy revenues due to a reduction in the commencement of new services during the COVID-19 pandemic and reductions in commercial Payor reimbursement rates. |
| ● | OSA treatment. Net revenues increased 10.8% primarily due to organic growth in OSA treatment equipment and related supplies, as well as higher reimbursement levels. |
| ● | NPWT. Net revenues increased 6.7% primarily due to increased reimbursement levels. |
| ● | Other equipment and services. Net revenues increased 1.0% primarily due to an increase in reimbursement levels partially offset by lower revenues resulting from reduced patient volumes. |
30
Revenues reimbursed under arrangements with Medicare and Medicaid were approximately 21% and 1%, respectively, of total net revenues for the three months ended June 30, 2021 and June 30, 2020.
Cost of Net Revenues and Gross Margin.
Cost of Net Revenues. Cost of net revenues for the three months ended June 30, 2021 was $84.7 million compared to $80.9 million for the three months ended June 30, 2020, an increase of $3.9 million or 4.8%. The increase in cost of net revenues for the three months ended June 30, 2021 was primarily due to increased product and supply costs, increased other costs, and increased home respiratory therapists costs, partially offset by lower patient equipment depreciation as described below. Our cost of net revenues was as follows:
| | | | | | | | | | | | |
|
| Three Months Ended June 30, |
|
| |
|
|
| ||||
(dollar amounts in thousands) |
| 2021 |
| 2020 |
| Change $ |
| Change % | ||||
Product and supply costs | | $ | 50,599 | | $ | 47,307 | | $ | 3,292 |
| 7.0 | % |
Patient equipment depreciation | |
| 25,159 | |
| 25,655 | |
| (496) |
| (1.9) | % |
Home respiratory therapists costs | |
| 4,264 | |
| 3,780 | |
| 484 |
| 12.8 | % |
Other | |
| 4,726 | |
| 4,125 | |
| 601 |
| 14.6 | % |
Total cost of net revenues | | $ | 84,748 | | $ | 80,867 | | $ | 3,881 |
| 4.8 | % |
Product and supply costs increased primarily to support increased volume in OSA treatment supplies.
Patient equipment depreciation costs decreased primarily as a result of lower sleep equipment purchases due to a reduction in new patient set-ups during the COVID-19 pandemic, partially offset by increased equipment purchases to support higher oxygen therapy volume.
Home respiratory therapists costs included within cost of net revenues increased primarily due to a higher percentage of respiratory therapists time being spent on clinical work.
Other costs increased due to an increased volume of patient equipment title transfers related to nonrecoverable equipment.
Gross Margin. Gross margin for the three months ended June 30, 2021 was 70.4% compared to 69.9% for the three months ended June 30, 2020, an increase of 50 basis points. The gross margin increase was primarily driven by higher reimbursement levels, which was partially offset by an increase in capitation contract utilization as we experienced a decline in utilization during the COVID-19 pandemic in the prior year.
Selling, Distribution and Administrative. SD&A expenses for the three months ended June 30, 2021 were $169.3 million compared to $174.8 million for the three months ended June 30, 2020, a decrease of $5.5 million or 3.2%. SD&A expenses for the three months ended June 30, 2021 were 59.1% of total net revenues compared to 65.0% of total net revenues for the three months ended June 30, 2020. The decrease was primarily due to a $10.8 million reduction in one-time expense associated with the settlement of a series of civil investigative demands in the prior year, lower incentive compensation based on achievement to plan, and a decrease in one-time costs associated with project Simplify. See further discussion at Note 7 - Commitments and Contingencies in our unaudited condensed consolidated financial statements for more information. The decrease was partially offset by increased variable costs associated with volume growth, increased costs associated with being a public company, higher stock compensation expense due to current year grants including a one-time initial public offering (the “IPO” or “offering”) grant, and one-time costs associated with a follow-on public offering. As we did not receive any proceeds from the offering, these costs were expensed as incurred in SD&A expenses in the unaudited condensed consolidated statements of income.
Income Tax Expense. Income tax expense for the three months ended June 30, 2021 was $8.8 million compared to $4.0 million for the three months ended June 30, 2020, an increase of $4.8 million or 119.9%. Our effective tax rate was 29.9% and 33.0% for the three months ended June 30, 2021 and 2020, respectively. The change in income tax expense was primarily a result of an increase in taxable operating income. For the three months ended June 30, 2021, the
31
effective tax rate differed from federal and state statutory rates primarily due to non-deductible executive compensation and non-deductible public offering costs.
Comparison of Six Months Ended June 30, 2021 and Six Months Ended June 30, 2020.
The following table summarizes our consolidated results of operations:
| | | | | | | | | | | | |
| | Six Months Ended June 30, | | | | | |
| ||||
(dollar amounts in thousands) |
| 2021 |
| 2020 |
| Change $ |
| Change % | ||||
Net revenues | | $ | 561,553 | | $ | 538,168 | | $ | 23,385 |
| 4.3 | % |
Cost of net revenues, including related depreciation | |
| 171,666 | |
| 165,221 | |
| 6,445 |
| 3.9 | % |
Gross margin | |
| 389,887 | |
| 372,947 | |
| 16,940 |
| 4.5 | % |
Selling, distribution and administrative | |
| 346,563 | |
| 349,436 | |
| (2,873) |
| (0.8) | % |
Total costs and expenses | |
| 518,229 | |
| 514,657 | |
| 3,572 |
| 0.7 | % |
Operating income | |
| 43,324 | |
| 23,511 | |
| 19,813 |
| 84.3 | % |
Interest expense | |
| 5,944 | |
| 2,930 | |
| 3,014 |
| 102.9 | % |
Interest income | |
| (91) | |
| (378) | |
| 287 |
| (75.9) | % |
Income tax expense | |
| 12,351 | |
| 6,391 | |
| 5,960 |
| 93.3 | % |
Net income | | $ | 25,120 | | $ | 14,568 | | $ | 10,552 |
| 72.4 | % |
| | | | | | | | | | | | |
Net Revenues. Net revenues for the six months ended June 30, 2021 were $561.6 million compared to $538.2 million for the six months ended June 30, 2020, an increase of $23.4 million or 4.3%. The increase in net revenues for the six months ended June 30, 2021 was primarily due to growth in OSA treatment and home respiratory therapy. The increase was partially offset by reduced demand for certain products and services associated with elective medical procedures and the disruption in physician practices (such as commencement of new ventilation therapy and other equipment and services) during the COVID-19 pandemic. The increase in net revenues was also due to higher reimbursement levels and increased Medicare reimbursement rates from the CARES Act, the temporary suspension of Medicare sequestration, and oxygen budget neutrality, partially offset by reductions in commercial Payor reimbursement rates. Our core services comprise total net revenues as follows:
| | | | | | | | | | | | |
|
| Six Months Ended June 30, |
|
| |
|
|
| ||||
(dollar amounts in thousands) |
| 2021 |
| 2020 |
| Change $ |
| Change % | ||||
Home respiratory therapy | | $ | 230,328 | | $ | 221,282 | | $ | 9,046 |
| 4.1 | % |
OSA treatment | |
| 235,664 | |
| 218,984 | |
| 16,680 |
| 7.6 | % |
NPWT | |
| 20,384 | |
| 19,790 | |
| 594 |
| 3.0 | % |
Other equipment and services | |
| 75,177 | |
| 78,112 | |
| (2,935) |
| (3.8) | % |
Net revenues | | $ | 561,553 | | $ | 538,168 | | $ | 23,385 |
| 4.3 | % |
Net revenues for the six months ended June 30, 2021 increased primarily due to the following:
| ● | Home respiratory therapy. Net revenues increased 4.1% primarily due to increased volume of patients requiring oxygen therapy, increased Medicare reimbursement rates from the CARES Act, the temporary suspension of Medicare sequestration, and oxygen budget neutrality, as well as higher reimbursement levels. The increase was partially offset by lower ventilation therapy revenues due to a reduction in the commencement of new services during the COVID-19 pandemic and a reduction in commercial Payor reimbursement rates. |
| ● | OSA treatment. Net revenues increased 7.6% primarily due to organic growth in OSA treatment supplies and equipment, higher reimbursement levels and increased Medicare reimbursement rates from the CARES Act, and the temporary suspension of Medicare sequestration. The increase was partially offset by reductions in commercial Payor reimbursement rates. |
| ● | NPWT. Net revenues increased 3.0% primarily due to higher reimbursement levels. |
32
| ● | Other equipment and services. Net revenues decreased 3.8% primarily due to a decrease in other respiratory therapy volume partially resulting from reduced patient volumes and a reduction in demand associated with elective medical procedures and the disruption in physician practices during the COVID-19 pandemic. The decrease was partially offset by higher reimbursement levels. |
Revenues reimbursed under arrangements with Medicare and Medicaid were approximately 21% and 1%, respectively, of total net revenues for the six months ended June 30, 2021. Revenues reimbursed under arrangements with Medicare and Medicaid were approximately 19% and 1%, respectively, of total net revenues for the six months ended June 30, 2020.
Cost of Net Revenues and Gross Margin.
Cost of Net Revenues. Cost of net revenues for the six months ended June 30, 2021 was $171.7 million compared to $165.2 million for the six months ended June 30, 2020, an increase of $6.4 million or 3.9%. The increase in cost of net revenues for the six months ended June 30, 2021 was primarily due to increased product and supply costs, offset by lower other costs and lower home respiratory therapists costs as described below. Our cost of net revenues was as follows:
| | | | | | | | | | | | |
|
| Six Months Ended June 30, |
|
| |
|
|
| ||||
(dollar amounts in thousands) |
| 2021 |
| 2020 |
| Change $ |
| Change % | ||||
Product and supply costs | | $ | 103,914 | | $ | 96,371 | | $ | 7,543 |
| 7.8 | % |
Patient equipment depreciation | |
| 50,885 | |
| 50,736 | |
| 149 |
| 0.3 | % |
Home respiratory therapists costs | |
| 8,322 | |
| 8,862 | |
| (540) |
| (6.1) | % |
Other | |
| 8,545 | |
| 9,252 | |
| (707) |
| (7.6) | % |
Total cost of net revenues | | $ | 171,666 | | $ | 165,221 | | $ | 6,445 |
| 3.9 | % |
Product and supply costs increased primarily to support increased volume in OSA treatment supplies and oxygen therapy.
Patient equipment depreciation costs increased primarily as a result of equipment purchases to support increased volume in oxygen therapy, partially offset by lower sleep equipment purchases due to a reduction in new patient set-ups during the COVID-19 pandemic.
Home respiratory therapists costs decreased primarily due to reduced demand for certain services associated with elective medical procedures and the disruption in physician practices, as well as operational efficiencies during the COVID-19 pandemic. The decrease was partially offset by an increase in the percentage of respiratory therapist time being spent on clinical work.
Other costs decreased as a result of a lower volume of sales or title transfers to patients driven by different contractual requirements during the COVID-19 pandemic, partially offset by an increase in volume of patient equipment title transfers related to nonrecoverable equipment.
Gross Margin. Gross margin for the six months ended June 30, 2021 was 69.4% compared to 69.3% for the six months ended June 30, 2020, an increase of 10 basis points. The gross margin increase was driven by higher reimbursement levels and increased Medicare reimbursement rates from the CARES Act, the temporary suspension of Medicare sequestration, and oxygen budget neutrality. The favorability was offset by a decrease in commercial Payor reimbursement rates and an increase in capitation contract utilization as we experienced a decline in utilization during the COVID-19 pandemic in the prior year.
Selling, Distribution and Administrative. SD&A expenses for the six months ended June 30, 2021 were $346.6 million compared to $349.4 million for the six months ended June 30, 2020, a decrease of $2.9 million or 0.8%. SD&A expenses for the six months ended June 30, 2021 were 61.7% of total net revenues compared to 64.9% of total net revenues for the six months ended June 30, 2020. The decrease was primarily due a $12.8 million reduction in a one-time expense associated with the settlement of a series of civil investigative demands in the prior year, a reduction in
33
salaries and wages as a percentage of total net revenues as a result of a reduction in overall headcount associated with operational efficiencies and one less business day, lower incentive compensation based on achievement to plan, and a decrease in one-time costs associated with project Simplify. See further discussion at Note 7 - Commitments and Contingencies in our unaudited condensed consolidated financial statements for more information. The decrease was partially offset by variable costs associated with volume growth, one-time costs associated with public offerings, increased stock compensation expense due to current year grants including a one-time IPO grant, increased costs associated with being a public company, and a legal settlement of a claim brought under the Private Attorneys General Act of California. As we did not receive any proceeds from the public offerings, these costs were expensed as incurred in SD&A expenses in the unaudited condensed consolidated statements of income.
Income Tax Expense. Income tax expense for the six months ended June 30, 2021 was $12.4 million compared to $6.4 million for the six months ended June 30, 2020, an increase of $6.0 million or 93.3%. Our effective tax rate was 33.0% and 30.5% for the six months ended June 30, 2021 and 2020, respectively. The change in income tax expense was primarily a result of an increase in taxable operating income. For the six months ended June 30, 2021, the effective tax rate differed from federal and state statutory rates primarily due to non-deductible executive compensation and non-deductible public offering costs.
Liquidity and Capital Resources
Our principal source of liquidity is our operating cash flow, which is supplemented by extended payment terms from our suppliers and our Revolving Credit Facility (the “Revolver”), which provides for revolving credit of up to $100.0 million, subject to availability. Our principal liquidity requirements are labor costs, including salaries, bonuses, benefits and travel-related expenses, product and supply costs, third-party customer service, billing and collections and logistics costs and patient equipment capital expenditures. Our future capital expenditure requirements will depend on many factors, including our revenue growth rates. Our capital expenditures are made in advance of patients beginning service. Certain operating costs are incurred at the beginning of the equipment rental period and during initial patient set up. We may be required to seek additional equity or debt financing. In the event that additional financing is required from outside sources, we may not be able to raise it on terms acceptable to us or at all. If we are unable to raise additional capital when desired, our business, results of operations, and financial condition would be materially and adversely affected. We believe that our operating cash flow, together with our existing cash, cash equivalents, and Revolver, will continue to be sufficient to fund our operations and growth strategies for at least the next 12 months.
Apria, Inc. is a holding company and our operations will be conducted entirely through our subsidiaries. Our ability to generate cash to pay applicable taxes at assumed tax rates and pay cash dividends we declare, if any, is dependent on the earnings and the receipt of funds from Apria Healthcare Group Inc. (“Apria Healthcare Group”) and its subsidiaries via dividends or intercompany loans. Deterioration in the financial condition, earnings or cash flow of Apria Healthcare Group and its subsidiaries for any reason could limit or impair their ability to pay such distributions. Additionally, the terms of our financing arrangements, including the Term Loan A Facility (the “TLA”) and the Revolver, contain covenants that may restrict Apria Healthcare Group and its subsidiaries from paying such distributions, subject to certain exceptions.
On December 11, 2020, we entered into the credit facility amendment to incur $260.0 million of Incremental Term Loans. Net proceeds from the Incremental Term Loans were used to fund a $200.3 million dividend payment to our stockholders and a $9.7 million distribution to stock appreciation rights (“SARs”) holders declared and paid in December 2020, with the remaining proceeds used to pay fees and expenses in connection with the credit facility amendment and for general corporate purposes. We also declared and paid a $175.0 million dividend to common stockholders and SARs holders payable in June 2019 and a $75.0 million dividend to common stockholders in July 2018. We have no current plans to pay dividends on our common stock.
As permitted under the CARES Act, we have elected to defer certain portions of employer-paid FICA taxes otherwise payable from March 27, 2020 to January 1, 2021, which will be paid in two equal installments on December 31, 2021 and December 31, 2022. The amount deferred as of June 30, 2021 was $14.8 million.
34
Cash Flow. The following table presents selected data from our unaudited condensed consolidated statement of cash flows:
| | | | | | |
| | Six Months Ended | ||||
| | June 30, | ||||
(in thousands) | | 2021 | | 2020 | ||
Net cash provided by operating activities | | $ | 82,635 | | $ | 84,598 |
Net cash used in investing activities | | | (53,865) | | | (46,354) |
Net cash used in financing activities | | | (18,023) | | | (13,189) |
Net decrease in cash and cash equivalents | | | 10,747 | | | 25,055 |
Cash and cash equivalents at beginning of period | | | 195,197 | | | 74,691 |
Cash and cash equivalents at end of period | | $ | 205,944 | | $ | 99,746 |
Comparison of Six Months Ended June 30, 2021 and June 30, 2020. Net cash provided by operating activities for the six months ended June 30, 2021 was $82.6 million compared to $84.6 million for the six months ended June 30, 2020, a decrease of $2.0 million. The decrease in net cash provided by operating activities was primarily the result of the following:
| ● | $22.3 million net decrease in cash resulting from the change in operating assets and liabilities, due primarily to the decrease in cash provided by accounts receivable of $10.4 million, a decrease in legal reserves of $11.6 million, a decrease in cash provided by accrued expenses of $6.1 million, and an increase in cash used in accrued payroll and related taxes and benefits of $8.7 million, partially offset by a decrease in cash used for accounts payable of $15.6 million; partially offset by |
| ● | $10.6 million increase in net income; and |
| ● | $9.8 million increase in non-cash items primarily due to increase in stock-based compensation and use of deferred tax assets. |
Net cash used in investing activities for the six months ended June 30, 2021 was $53.9 million, compared to $46.4 million for the six months ended June 30, 2020, an increase in cash used of $7.5 million. The primary use of funds in the six months ended June 30, 2021 was $61.2 million to purchase patient equipment and property, equipment and improvements, which was partially offset by proceeds from the sale of patient equipment and other of $8.0 million. The primary use of funds in the six months ended June 30, 2020 was $55.9 million to purchase patient equipment and property, equipment and improvements, which was partially offset by proceeds from the sale of patient equipment and other of $9.6 million.
Net cash used in financing activities for the six months ended June 30, 2021 was $18.0 million compared to $13.2 million for the six months ended June 30, 2020, an increase of cash used of $4.8 million. Net cash used in financing activities for the six months ended June 30, 2021 primarily reflected payments on long-term debt of $10.4 million, payments on asset financing of $6.0 million, and payments on tax withholdings from equity-based compensation activity of $1.1 million. Net cash used in financing activities for the six months ended June 30, 2020 primarily reflected payments on asset financing of $13.2 million.
Non-GAAP Financial Information.
EBITDA, Adjusted EBITDA and Adjusted EBITDA less Patient Equipment Capex. EBITDA is a non-GAAP measure that represents net income for the period before the impact of interest income, interest expense, income taxes, and depreciation and amortization. EBITDA is widely used by securities analysts, investors and other interested parties to evaluate the profitability of companies. EBITDA eliminates potential differences in performance caused by variations in capital structures, tax positions, the cost and age of tangible assets and the extent to which intangible assets are identifiable. Adjusted EBITDA is a non-GAAP measure that represents EBITDA before certain items that impact comparison of the performance of our business either period-over-period or with other businesses. We use Adjusted EBITDA as a key profitability measure to assess the performance of our business. We believe that Adjusted EBITDA
35
should, therefore, be made available to securities analysts, investors and other interested parties to assist in their assessment of the performance of our business.
Adjusted EBITDA less Patient Equipment Capex is a non-GAAP measure that represents Adjusted EBITDA less purchases of patient equipment net of dispositions (“Patient Equipment Capex”). For purposes of this metric, Patient Equipment Capex is measured as the value of the patient equipment received less the net book value of dispositions of patient equipment during the accounting period. We use Adjusted EBITDA less Patient Equipment Capex as a key profitability measure to assess the performance of our business because our business requires significant capital expenditures to maintain its patient equipment fleet. Some equipment transfers title to patients’ ownership after a prescribed number of fixed monthly rental periods due to contractual commitments. Equipment that does not transfer title wears out or oftentimes is not recovered after a patient’s use of the equipment terminates. We believe that Adjusted EBITDA less Patient Equipment Capex should, therefore, be made available to securities analysts, investors and other interested parties to assist in their assessment of the performance of our business.
Below, we have provided a reconciliation of EBITDA, Adjusted EBITDA and Adjusted EBITDA less Patient Equipment Capex to our net income, the most directly comparable financial measure calculated and presented in accordance with GAAP. EBITDA, Adjusted EBITDA and Adjusted EBITDA less Patient Equipment Capex should not be considered alternatives to net income or any other measure of financial performance calculated and presented in accordance with GAAP. Our EBITDA, Adjusted EBITDA and Adjusted EBITDA less Patient Equipment Capex may not be comparable to similarly titled measures of other organizations because other organizations may not calculate EBITDA, Adjusted EBITDA and Adjusted EBITDA less Patient Equipment Capex in the same manner as we calculate these measures.
Our uses of EBITDA, Adjusted EBITDA and Adjusted EBITDA less Patient Equipment Capex have limitations as analytical tools, and you should not consider them in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:
| ● | although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, EBITDA and Adjusted EBITDA do not reflect capital expenditure requirements for such replacements or other contractual commitments; |
| ● | EBITDA, Adjusted EBITDA and Adjusted EBITDA less Patient Equipment Capex do not reflect changes in, or cash requirements for, our working capital needs; |
| ● | EBITDA, Adjusted EBITDA and Adjusted EBITDA less Patient Equipment Capex do not reflect the interest expense or the cash requirements necessary to service interest or principal payments on our indebtedness; and |
| ● | other companies, including companies in our industry, may calculate EBITDA, Adjusted EBITDA and Adjusted EBITDA less Patient Equipment Capex measures differently, which reduces their usefulness as a comparative measure. |
EBITDA, Adjusted EBITDA and Adjusted EBITDA less Patient Equipment Capex exclude items that can have a significant effect on our profit or loss and should, therefore, be used in conjunction with, not as substitutes for, profit or loss for the period. We compensate for these limitations by separately monitoring net income from continuing operations for the period.
36
The following table reconciles net income, the most directly comparable GAAP measure, to EBITDA, Adjusted EBITDA and Adjusted EBITDA less Patient Equipment Capex:
| | | | | | | | | | | | | |
|
| Three Months Ended June 30, |
|
| Six Months Ended June 30, | ||||||||
(in thousands) |
| 2021 |
| 2020 |
|
| 2021 |
| 2020 | ||||
Net income | | $ | 20,576 | | $ | 8,129 | | | $ | 25,120 | | $ | 14,568 |
Interest expense, net | |
| 2,892 | |
| 1,156 | | |
| 5,853 | |
| 2,552 |
Income tax expense | |
| 8,788 | |
| 3,997 | | |
| 12,351 | |
| 6,391 |
Depreciation and amortization | |
| 28,972 | |
| 29,544 | | |
| 58,585 | |
| 58,191 |
EBITDA | | $ | 61,228 | | $ | 42,826 | | | $ | 101,909 | | $ | 81,702 |
Strategic transformation initiatives: | |
|
| |
|
| | |
|
| |
|
|
Simplify(a) | | $ | — | | $ | 787 | | | $ | — | | $ | 837 |
Financial system(b) | |
| 382 | |
| 547 | | |
| 741 | |
| 1,063 |
Other initiatives(c) | |
| 39 | |
| 12 | | |
| 39 | |
| 45 |
Stock-based compensation one-time award at IPO(d) | | | 491 | | | — | | | | 2,440 | | | — |
Stock-based compensation(e) | |
| 1,526 | |
| 749 | | |
| 2,295 | |
| 1,323 |
Legal settlements(f) | |
| — | |
| 10,800 | | |
| 1,750 | |
| 12,800 |
Offering costs(g) | |
| 685 | |
| — | | |
| 3,452 | |
| — |
Adjusted EBITDA | | $ | 64,351 | | $ | 55,721 | | | $ | 112,626 | | $ | 97,770 |
Patient Equipment Capex | |
| (20,250) | |
| (12,588) | | |
| (43,782) | |
| (37,057) |
Adjusted EBITDA less Patient Equipment Capex | | $ | 44,101 | | $ | 43,133 | | | $ | 68,844 | | $ | 60,713 |
| (a) | Simplify represents one-time advisory fees and implementation costs associated with a key 2019 business transformation initiative focused on shifting to a patient-centric platform and optimizing end-to-end customer service. |
| (b) | Costs associated with the implementation of a new financial system. |
| (c) | Other initiatives include one-time costs associated with customer service initiatives and costs associated with moving the corporate headquarters. |
| (d) | The offering resulted in a one-time restricted stock unit (“RSUs”) grant to the Company’s CFO. The RSUs vest in tranches and are classified as liability awards since each tranche of RSUs can be settled in either cash or shares of our common stock at the CFO’s election. The first tranche of RSUs vested upon completion of the IPO and was settled in cash. Compensation expense for the remaining tranches is recognized over the requisite service period subject to continued employment and adjusted each reporting period for changes in the fair value pro-rated for the portion of the requisite service period rendered until settlement. |
| (e) | Stock-based compensation has historically been granted to certain of our employees and non-employee directors in the form of profit interest units of Apria Holdings LLC, RSUs, performance-based RSUs, and SARs. For time-based only RSUs and SARs, compensation expense for each separately vesting portion of the award is recognized on a straight-line basis over the vesting period for that portion of the award subject to continued service. For RSUs with performance conditions, compensation expense is recognized over the requisite service period subject to management’s estimation of the probability of vesting of such awards. Stock compensation also includes expense related to the Company’s LTIP which will be settled in stock. |
| (f) | In 2021, the amount represents the final settlement amount of a claim brought under the Private Attorneys General Act of California. In 2020, the amount represents the increase in the settlement amount in relation to a series of civil investigative demands from the United States Attorney’s Office for the Southern District of New York. See further discussion at Note 7 - Commitments and Contingencies in our unaudited condensed consolidated financial statements for more information. |
| (g) | Offering costs represent one-time costs relating to preparation for our IPO and follow-on offering. As the Company did not receive any proceeds from the offerings, these costs were expensed as incurred in SD&A expenses in the unaudited condensed consolidated statements of income. |
Contractual Obligations. There were no material changes to our contractual obligations from what we previously disclosed in our 2020 Form 10-K.
37
Accounts Receivable. Accounts receivable increased to $77.6 million as of June 30, 2021 from $74.8 million at December 31, 2020, an increase of $2.9 million. Days sales outstanding (calculated as of each period-end by dividing accounts receivable, net by the rolling average of total net revenues) were 31 days at June 30, 2021 compared to 29 days at December 31, 2020. The increase in accounts receivable for the six months ended June 30, 2021 was primarily due to seasonality of patient deductibles and increased volume.
Unbilled Receivables. Included in accounts receivable are earned but unbilled receivables of $14.2 million and $13.1 million at June 30, 2021 and December 31, 2020, respectively. Delays, ranging from a single day to several weeks, between the date of service and billing can occur due to delays in obtaining certain required Payor-specific documentation from internal and external sources. Earned but unbilled receivables are aged from date of service and are considered in our analysis of historical performance and collectability.
Inventories and Patient Equipment. Inventories consist primarily of respiratory supplies and items used in conjunction with patient equipment. Patient equipment consists of respiratory and home medical equipment that is provided to in-home patients for the course of their care plan, normally on a rental basis, and subsequently returned to us for redistribution after cleaning and maintenance is performed. We maintain inventory and patient equipment at levels we believe will provide for the needs of our patients.
Long-Term Debt. On June 21, 2019, we entered into a credit agreement with Citizens Bank and a syndicate of lenders for both a TLA of $150.0 million and a Revolver of $100.0 million. Proceeds from the TLA were used to fund a $175.0 million dividend payment to common stockholders and distribution to SARs holders. On December 11, 2020, we entered into the credit facility amendment to obtain $260.0 million of Incremental Term Loans. Net proceeds from the Incremental Term Loans were used to fund a $200.3 million dividend payment to our stockholders and a $9.7 million distribution to SARs holders declared and paid in December 2020, with the remaining proceeds used to pay fees and expenses in connection with the credit facility amendment and for general corporate purposes.
The credit agreement permits the interest rate to be selected at our option at either adjusted London Interbank Offered Rate (“Adjusted LIBOR”) or alternative base rate plus their respective applicable margin. Adjusted LIBOR is the rate for Eurodollar deposits for the applicable interest period while the Alternate Base Rate is the highest of (i) the Administrative Agent’s “Prime Rate”, (ii) the Federal Funds Effective Rate plus 0.50%, and (iii) one-month Adjusted LIBOR plus 1.00%. Furthermore, Adjusted LIBOR is subject to a 0.50% per annum floor and the alternative base rate is subject to a 1.50% per annum floor. Additionally, the margin applied to both the TLA and Revolver is determined based on total net leverage ratio. Total net leverage ratio is defined as net debt, which represents indebtedness minus up to $25.0 million in cash and cash equivalents over consolidated EBITDA as defined under the credit agreement. The following is a summary of the additional margin and commitment fees payable on both the TLA and available Revolver:
| | | | | | | | | | | |
| | |
| Applicable Margin | | Applicable Margin | | | |||
| | | | for Adjusted | | for Alternative | | Commitment | |||
Level |
| Total Net Leverage Ratio | | LIBOR Loans | | Base Rate Loans | | Fee | |||
I |
| Greater than or equal to 3.00x |
| 2.75 | % | | 1.75 | % | | 0.35 | % |
II |
| Greater than or equal to 2.50x but less than 3.00x |
| 2.50 | % | | 1.50 | % | | 0.30 | % |
III |
| Greater than or equal to 1.50x but less than 2.50x |
| 2.25 | % | | 1.25 | % | | 0.25 | % |
IV |
| Less than 1.50x |
| 2.00 | % | | 1.00 | % | | 0.20 | % |
38
The TLA matures on June 21, 2024 and we are required to make quarterly principal payments on the TLA beginning June 30, 2020. Upon entering into the credit facility amendment the amount of those quarterly principal payments was adjusted to account for the Incremental Term Loans. We expect to refinance, renew or replace the TLA prior to its maturity in June 2024 or to repay it with cash from operations. The table below is a summary of the expected timing of remaining principal repayments each fiscal year:
| | | |
(in thousands) |
| | |
2021 (remainder) | | $ | 10,417 |
2022 | |
| 36,458 |
2023 | |
| 41,667 |
2024 | |
| 302,083 |
The credit agreement encompassing the TLA and Revolver permits, subject to certain exceptions, an increase in our TLA or our Revolver, as well as the ability to incur additional indebtedness, as long as it does not exceed a total net leverage ratio of 3.00x. The credit agreement requires mandatory prepayments upon the occurrence of certain events, such as dispositions and casualty events, subject to certain exceptions. The TLA or Revolver may be voluntarily prepaid at any time without any premium or penalty.
Apria Healthcare Group’s assets and equity interests of Apria Healthcare Group and all present and future wholly-owned direct domestic subsidiaries of Apria Healthcare Group, with certain exceptions, are pledged as collateral for the TLA and Revolver. The credit agreement contains a financial covenant requiring us to maintain a total net leverage ratio less than 3.50x. The credit agreement also contains negative covenants that, among other things, restrict, subject to certain exceptions, the ability of Apria Healthcare Group and its restricted subsidiaries to incur additional indebtedness and guarantee indebtedness, create or incur liens, engage in mergers or consolidations, dispose of assets, pay dividends and distributions or repurchase capital stock, repay certain indebtedness, make investments and engage in certain transactions with affiliates.
As of June 30, 2021, no amounts were outstanding under the Revolver, there were $15.8 million outstanding letters of credit, and additional availability under the Revolver net of letters of credit outstanding was $84.2 million. We were in compliance with all debt covenants set forth in the TLA and Revolver as of June 30, 2021.
In accordance with ASU 2015-03, Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs, we record origination and other expenses related to certain debt issuance costs as a direct deduction from the carrying amount of the debt liability. These expenses are deferred and amortized using the straight-line method over the stated life, which approximates the effective interest rate method. Amortization of deferred debt issuance costs are classified within interest expense in our unaudited condensed consolidated statements of income and was $0.5 million and $0.2 million for the six months ended June 30, 2021 and 2020, respectively.
Interest expense, excluding deferred debt issuance costs discussed above, was $5.4 million and $2.7 million for the six months ended June 30, 2021 and 2020, respectively. The interest rate was 2.50% as of June 30, 2021 and December 31, 2020. Interest paid on debt totaled $5.4 million and $2.7 million for the six months ended June 30, 2021 and 2020, respectively.
Commitments and Contingencies
From time to time we enter into certain types of contracts that contingently require us to indemnify parties against third-party claims. The contracts primarily relate to: (i) certain asset purchase agreements, under which we may provide customary indemnification to the seller of the business being acquired; (ii) certain real estate leases, under which we may be required to indemnify property owners for environmental and other liabilities, and other claims arising from our use of the applicable premises; and (iii) certain agreements with our officers, directors and employees, under which we may be required to indemnify such persons for liabilities arising out of their relationship with us. In addition, we issued certain letters of credit under our Credit Facility as described under “Liquidity and Capital Resources—Long-Term Debt” above.
39
The terms of such obligations vary by contract and in most instances a specific or maximum dollar amount is not explicitly stated therein. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, no liabilities have been recorded for these obligations on our balance sheets for any of the periods presented.
Critical Accounting Policies and Estimates
The preparation of our unaudited condensed consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect reported amounts and related disclosures. We have discussed the policies and estimates that we believe are critical and require the use of complex judgment in their application in our 2020 Form 10-K. There have been no material changes in the Company’s critical accounting policies as compared to the critical accounting policies described in the Company’s 2020 Form 10-K.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Our exposure to market risk relates to fluctuations in interest rates from borrowings under the Credit Facility. Our letter of credit fees and interest accrued on our debt borrowings carry a floating interest rate which is tied either to Adjusted LIBOR or alternative base rate plus their respective applicable margin and therefore are exposed to changes in interest rates. As of June 30, 2021, there was $390.6 million outstanding on the TLA, $15.8 million outstanding letters of credit, and additional availability under the Revolver, net of letters of credit outstanding, was $84.2 million.
Item 4. Controls and Procedures
Disclosure Controls and Procedures
The Company maintains a set of disclosure controls and procedures designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms. Any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance of achieving the desired control objectives. The Company’s management, with the participation of the Company’s Chief Executive Officer, and the Company’s Chief Financial Officer, has evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon that evaluation, the Company’s Chief Executive Officer and the Company’s Chief Financial Officer concluded that, as of June 30, 2021, the Company’s disclosure controls and procedures were effective to accomplish their objectives at the reasonable assurance level.
Changes in Internal Control over Financial Reporting
There has been no change in our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
PART II — OTHER INFORMATION
Item 1. Legal Proceedings
The information required with respect to this Item 1 can be found under Note 7 – Commitments and Contingencies to the unaudited condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
40
Item 1A. Risk Factors
In addition to the other information set forth in this report, you should carefully consider the factors discussed in our 2020 Form 10-K, which could materially affect our business, financial condition or future results. Except for the revised risk factor below, there have been no material changes to the risk factors disclosed in our 2020 Form 10-K. The risks described in our 2020 Form 10-K are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.
A recall of any of our products, either voluntarily or at the direction of the Food and Drug Administration (“FDA”) or another governmental authority, or the discovery of serious safety issues with our products that leads to corrective actions being taken, could have a significant adverse impact on our business.
The FDA has authority to request the recall of medical gas products or medical devices in the event a product presents a risk of illness or injury or gross consumer deception, such as due to a material deficiency or defect in design, labeling or manufacture of a product, and a cessation of distribution and/or recall is necessary to protect the public health and welfare. If after providing the Company or the manufacturer with an opportunity to consult with the agency, the FDA finds that there is a reasonable probability that a device intended for human use would cause serious, adverse health consequences or death, the FDA has the power to mandate a recall of medical devices. Manufacturers may also, under their own initiative, recall a product if any material deficiency is identified or withdraw a product for other reasons. For example, in June 2021, one of our suppliers, Philips Respironics, announced a voluntary recall for continuous and non-continuous ventilators (certain CPAP, BiLevel positive airway pressure and ventilator devices) related to polyurethane foam used in those devices. The FDA has since identified this as a Class I recall, the most serious category of recall. Because we distribute these products and provide related home respiratory services and, in part, due to the substantial number of impacted devices, our management team has devoted, and will likely continue to devote, substantial time and resources to coordinating recall-related activity and to supporting our home healthcare patients’ needs. This, or any other major recall, may cause us to incur significant costs, some or all of which may not be recoverable from the product manufacturer. The recall may also materially negatively affect our revenues and results of operations as a result of patients not using their impacted devices, current shortages in the availability of both replacement devices for impacted patients and new devices for new patients, patient hesitancy to use respiratory devices generally or other reasons.
In addition to the diversion of management attention and financial resources from the operation of our business, any major recall could cause the price of our stock to decline and expose us to product liability or other claims and harm our reputation with customers. If we do not adequately address problems associated with our drugs or devices, we may face additional regulatory enforcement action, FDA warning letters, product seizure, injunctions, administrative penalties, civil money penalties or criminal fines. We may also be required to bear other costs or take other actions that may have a negative impact on our sales, or significant adverse publicity of regulatory consequences, which could harm our business.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
41
Item 5. Other Information
None.
Item 6. Exhibits
Exhibit No. | Description |
| |
3.1 | Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on February 16, 2021) |
3.2 | Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed on February 16, 2021) |
10.1† | |
10.2† | |
10.3† | Form of Performance Stock Unit Agreement under the Apria, Inc. 2021 Omnibus Incentive Plan |
31.1† | Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
31.2† | Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
32.1†† | |
32.2†† | |
101.INS† | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document |
101.SCH† | Inline XBRL Taxonomy Extension Schema Document |
101.CAL† | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
101.DEF† | Inline XBRL Taxonomy Extension Definition Linkbase Document |
101.LAB† | Inline XBRL Taxonomy Extension Label Linkbase Document |
101.PRE† | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
104† | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) |
†† Furnished herewith.
The agreements and other documents filed as exhibits to this report are not intended to provide factual information or other disclosure other than with respect to the terms of the agreements or other documents themselves, and you should not rely on them for that purpose. In particular, any representations and warranties made by us in these agreements or other documents were made solely within the specific context of the relevant agreement or document and may not describe the actual state of affairs as of the date they were made or at any other time.
42
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, duly authorized.
Date: August 5, 2021
| | |
| APRIA, INC. | |
| | |
| By: | /s/ Daniel J. Starck |
| | Name: Daniel J. Starck |
| | Title: Chief Executive Officer |
| | (Principal Executive Officer) |
| | |
| By: | /s/ Debra L. Morris |
| | Name: Debra L. Morris |
| | Title: Chief Financial Officer |
| | (Principal Financial Officer) |
| | |
43
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 6/21/24 | ||||
| 12/31/22 | ||||
| 6/30/22 | ||||
| 12/31/21 | 10-K, 10-K/A | |||
| 9/30/21 | 10-Q | |||
| Filed as of: | 8/6/21 | |||
| Filed on: | 8/5/21 | 8-K, SC 13G | ||
| 7/30/21 | ||||
| 7/28/21 | ||||
| For Period end: | 6/30/21 | |||
| 3/31/21 | 10-K, 10-Q | |||
| 2/16/21 | 4, 8-K | |||
| 2/10/21 | 8-A12B, 8-K, EFFECT | |||
| 1/1/21 | ||||
| 12/31/20 | 10-K, DRS/A, DRSLTR | |||
| 12/18/20 | ||||
| 12/11/20 | ||||
| 6/30/20 | ||||
| 5/1/20 | ||||
| 3/31/20 | ||||
| 3/27/20 | ||||
| 3/13/20 | ||||
| 3/6/20 | ||||
| 12/31/19 | ||||
| 6/21/19 | ||||
| 3/22/18 | ||||
| 10/28/08 | ||||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/01/22 Apria, Inc. 10-K 12/31/21 87:11M Toppan Merrill Bridge/FA 2/22/22 Apria, Inc. DEFM14A 1:2.2M Donnelley … Solutions/FA 2/07/22 Apria, Inc. PREM14A 2/07/22 2:2M Donnelley … Solutions/FA 11/12/21 Apria, Inc. 424B4 1:525K Donnelley … Solutions/FA 11/08/21 Apria, Inc. S-1 5:814K Donnelley … Solutions/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/16/21 Apria, Inc. 8-K:1,3,5,8 2/10/21 5:446K Donnelley … Solutions/FA |